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Abstract 
 
Diabetic nephropathy is the most common cause of end stage kidney disease in the 
world. Newer diabetic medications have arrived over the last few years and promised  
better outcomes. However there is lack of experimental and clinical evidence in 
favour of better outcomes.  
 
The two most important drug categories that have emerged in this century are the 
dipeptidyl peptidase-4 inhibitors DPP4 inhibitors (DPP4i) and sodium glucose 
cotransporter inhibitors (SGLT2i). Their role in preventing diabetic nephropathy 
irrespective of their glycaemic benefits is unknown. The aim of our project is to 
demonstrate the renoprotective benefits of these newer medications. 
 
In this thesis we used endothelial nitric oxide synthase knock out (eNOS -/-) mice and 
induced type 1 diabetes using streptozotocin (STZ) injection. We studied the changes 
of diabetic nephropathy in these mice including clinical outcomes, biochemical 
changes, inflammatory and fibrotic pathways. We determined the outcomes of 
diabetic mice treated with an SGLT2 inhibitor. This study showed that SGLT2 
inhibitors might not have a beneficial role in preventing diabetic nephropathy when 
blood glucose levels were high. Subsequently we studied the role of DPP4i in 
preventing the interaction between DPP4 and cation independent mannose-6-
phosphate receptor (CIM6PR) in the setting of high glucose in an in vitro model using 
kidney proximal tubular cells. Our results showed that DPP4i reduced the interaction 
between DPP4 and CIM6PR possibly resulting in the prevention of activation of 
latent TGFß. We proved this subsequently in an in vivo model of STZ induced type 1 
	 V 
diabetes in eNOS -/- mice using two different DPP4i. We demonstrated that 
linagliptin and saxagliptin were was able to reduce tubulointerstitial fibronectin 
deposition in STZ induced type 1 diabetic in eNOS -/- mice . In addition we also 
showed that saxagliptin reduced markers of inflammation and renal hypertrophy. We 
showed reduced expression of pSmad2/3, a downstream marker of TGFß activation 
with both linagliptin and saxagliptin signifying the pathway, which is targeted by the 
DPP4i.  
 
Hence our studies have helped in partly identifying the puzzle of diabetic nephropathy 
and provide some answers on the role of newer anti diabetic agents in preventing it. 
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Diabetic nephropathy is the commonest cause of end stage kidney disease. This is 
responsible for significant morbidity and healthcare cost for the individual and the 
community. Diabetes causes progressive kidney disease through a number of 
mechanisms. Diabetes causes progressive glomerulosclerosis and tubulointerstitial 
fibrosis. The extent of tubulointerstitial fibrosis determines the degree of loss of 
kidney function.  
 
The management of diabetes has changed over the last decade with newer treatments 
including dipeptidyl peptidase 4 (DPP4) inhibitors and sodium glucose cotransporter 
2 (SGLT2) inhibitors heralding a paradigm shift in therapeutic approach. These drugs 
are used in association with metformin and insulin to improve glycaemic control. 
These drugs may have additional benefits in preventing diabetic complications, 
especially diabetic nephropathy, independent of benefits derived by glucose lowering. 
The aim of this study was to investigate the renoprotective benefits of these drugs 
independent of glucose lowering.  	
The proximal convoluted tubule is a very active part of the nephron and is involved in 
glucose and sodium reabsorption. Most of the filtered glucose is reabsorbed by 
sodium glucose cotransporter 2 (SGLT2) with the rest being reabsorbed by sodium 
glucose cotransporter 1 (SGLT1) [1]. In diabetes, there is increased filtration of 
glucose into the urine due to hyperglycaemia and a large proportion of this is 
reabsorbed by SGLT2 and the rest by SGLT1. Blocking of SGLT2 receptors resulted 
in prevention of glucose reabsorption and improvement in glycaemic parameters. 
Hyperfiltration is an early phenomenon in diabetic nephropathy. This may be related 
to increased proximal tubular sodium and glucose reabsorption in diabetes resulting in 
	 3 
tubuloglomerular feedback mediated increase in glomerular filtration [2].  Prevention 
of glucose reabsorption has also shown improvement in glucose induced 
hyperfiltration [3]. Hence we wanted to explore the dual benefits of SGLT2 
inhibitors, namely reduction of hyperfiltration injury and toxic effects of high glucose 
in prevention of progression of diabetic nephropathy. The specific aims of this study 
were 
a) To determine the benefits of SGLT2 inhibitor empagliflozin in preventing 
progression of diabetic nephropathy in an animal model of streptozotocin (STZ) 
induced Type 1 diabetes independent of glucose lowering. 
b) To compare the outcomes with current best practice management of diabetic 
nephropathy, namely renin angiotensin blockade with telmisartan, an angiotensin 
receptor blocker. 
This study showed that there was no renoprotective benefit in this animal model of 
type 1 diabetes in the setting of high blood glucose. 
 
Dipeptidyl peptidase peptidase 4 inhibitors (DPP4i) increase meal induced insulin 
release by preventing glucagon like peptide-1 (GLP-1) degradation by enzyme DPP4. 
This helps in prolonged duration of action of GLP-1, which stimulates insulin release. 
However DPP4i have other important roles to play apart form glycaemic benefits. 
Importantly DPP4 is well expressed in the kidney tubule and possibly plays a role in 
the progression of diabetic nephropathy through promotion of profibrotic pathways in 
diabetes. Animal studies have pointed to renoprotective benefits of DPP4i, although 
these studies have also shown improved glycaemic control making it difficult to 
determine the specific renoprotective benefits of DPP4i independent of its glycaemic 
benefits [4]. It has been previously been shown that the DPP4 inhibitor linagliptin 
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reduced the conversion of latent to active transforming growth factor ß (TGFß). It has 
also been shown that cation independent mannose-6-phosphate receptor (CIM6PR) 
plays an integral role in the activation of TGFß. We know that CIM6PR and DPP4 
colocalise on the cell membrane possibly promoting the activation of TGFß. We 
wanted to determine the mechanism by which DPP4i interact with CIM6PR and 
prevent the activation of TGFß in an in vitro model. We also wanted to explore the 
renoprotective benefits in an in vivo model of STZ induced type 1 diabetes. DPP4i are 
of two types, namely peptidomimetic and non peptidomimetic. Hence we wanted to 
explore the specific renoprotective benefits of both types of DPP4i independent of 
glucose lowering. The specific aims of this study were   
a) To determine the interaction between the CIM6PR and DPP4 in context of high 
glucose and to determine if the DPP4 inhibitor linagliptin reduces this high glucose 
induced interaction 
b) To determine the benefits of the non peptidomimetic DPP4 inhibitor linagliptin and 
the peptidomimetic inhibitor saxagliptin in preventing progression of diabetic 
nephropathy in an animal model of streptozotocin (STZ) induced Type 1 diabetes 
independent of glucose lowering. 
c) To compare the outcomes with current best practice management of diabetic 
nephropathy, namely renin angiotensin blockade with telmisartan, an angiotensin 
receptor blocker. 
 
This study revealed that linagliptin reduced high glucose induced interaction between 
CIM6PR and DPP4 and downstream markers of the TGFß pathway. This study also 
showed that saxagliptin was able to reduce downstream markers of the TGFß pathway 
and reduced tubulointerstitial collagen deposition.  
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This thesis consists of the following eight chapters: 
 
Chapter 1 provides a brief introduction to the research question in this thesis and the 
aims and objectives of the thesis. 
Chapter 2 is a peer reviewed publication in Current Opinion in Nephrology and 
Hypertension (Sodium glucose cotransporter 2 and the diabetic kidney) [5]. This 
provides a summary of literature regarding the role of SGLT2 in diabetic nephropathy 
and the available evidence at that time regarding the renal outcomes of SGLT2 
inhibitors. 
Chapter 3 is a peer reviewed publication in Expert Review in Clinical Pharmacology 
(Empagliflozin for the treatment of type 2 diabetes) [6]. This review looked at the 
pharmacological aspects of the study drug, empagliflozin and the available evidence 
on renal outcomes from animal based studies and clinical trials. 
Chapter 4 is a peer reviewed publication in PLoS One (Inhibition of kidney proximal 
tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 
diabetic eNOS knock out mice) [7]. The renal outcomes of empagliflozin treatment on 
STZ induced diabetic endothelial nitric oxide synthase knock out mice (eNOS -/-) 
were studied. Both clinical and histopathological parameters were determined and the 
expression of glucose transporters were determined in diabetic and control mice. 
Chapter 5 provides a summary of the current literature regarding DPP4i and the role 
of DPP4 inhibition and GLP-1 agonists on renal outcomes in diabetic nephropathy 
Chapter 6 is a peer reviewed publication in PLoS One (Linagliptin limits high 
glucose induced conversion of latent to active TGFß through interaction with 
CIM6PR and limits renal tubulointerstitial fibronectin) [8]. This chapter determined 
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the role of linagliptin, a non peptidomimetic DPP4 inhibitor, in preventing high 
glucose induced interaction between membrane bound DPP4 and CIM6PR. This 
chapter also looked at role of linagliptin on clinical parameters and in reducing 
tubulointerstitial fibronectin deposition in diabetic nephropathy in STZ induced 
diabetic eNOS -/- mice. 
Chapter 7 is a peer reviewed publication in Nephrology (Saxagliptin reduces renal 
tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes) [9]. This chapter 
determined the effect of saxagliptin, a peptidomimetic DPP4 inhibitor on clinical 
parameters and in preventing inflammation and fibrosis in STZ induced diabetic 
eNOS -/- mice. 
Chapter 8 provides a summary and updated clinical evidence regarding the role of 
SGLT2 inhibitors and DPP4i since the publication of the above mentioned chapters. It 
also describes the future direction of research with regards to these agents in 
preventing diabetic nephropathy and improving cardiovascular outcomes. 
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Chapter 2: SGLT2 and the diabetic kidney 
 
Komala MG, Panchapakesan U, Pollock C, Mather A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Curr Opin Nephrol Hypertens. 2013 Jan;22(1):113-9. 
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Abstract 
 
Purpose of review 
Reabsorption of glucose in the proximal tubule occurs predominantly via the sodium 
glucose cotransporter 2 (SGLT2). There has been intense interest in this transporter as 
a number of SGLT2 inhibitors have entered clinical development. SGLT2 inhibitors 
act to lower plasma glucose by promoting glycosuria and this review aims to outline 
the effect on the diabetic kidney of this hypoglycaemic agent. 
 
Recent findings 
This review provides an overview of recent findings in this area: the transcriptional 
control of SGLT2 expression in human proximal tubular cells implicates a number of 
cytokines in the alteration of SGLT2 expression; experimental data show that SGLT2 
inhibition may correct early detrimental effects of diabetes by reducing proximal 
tubular sodium and glucose transport, suggesting a possible renoprotective effect 
independent of the glucose lowering effects of these agents; and the nonglycaemic 
effects of SGLT2 inhibitors may have an impact on renal outcomes. 
 
Summary 
The available clinical evidence shows consistent reduction in glycaemic parameters 
and some evidence suggests additional effects including weight loss and mild blood 
pressure reduction. There are some side effects that warrant further investigation and 
establishing whether SGLT2 inhibition provides a renal benefit relies on future long-
term studies with specific renal end-points. 
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2.1 Introduction 
 
Diabetic nephropathy is the most common cause of end stage kidney disease in the 
world. The prevalence of some degree of renal involvement in diabetic patients 
reaches 40 % [10] with significant progression to end stage disease. A treatment gap 
exists in the current prevention and treatment of diabetic nephropathy and 
implementing current best practice reduces this gap at best by 30%. Subsequently, 
there is significant interest in the role of sodium glucose co-transporter 2 (SGLT2) 
inhibitors with many drugs from this class in phase 3 clinical trials and some awaiting 
approval for licensing. These drugs act by blocking glucose reabsorption in the 
proximal tubule, resulting in increased glycosuria and a subsequent reduction in blood 
sugar levels. Whilst the use of SGLT2 inhibitors has been confirmed in clinical trials 
[11, 12] to result in improvement in glycaemic control, the renal effects are less well 
studied. They include potential benefits both from improved glycaemic control and 
from effects independent of glycaemic control such as, weight reduction, lowering of 
blood pressure with improved cardiovascular outcomes and unique renoprotective 
benefits. There are, however, also potential risks related to increased glycosuria 
including higher frequency of urinary infections, genital fungal infections, volume 
depletion and off target effects. This review will outline the current evidence in regard 
to both the renal risks and benefits of SGLT2 inhibitors. 
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2.2 Glucose and sodium absorption by the kidney 
 
Nearly 180 g of glucose is filtered in the glomerular filtrate everyday. The kidney 
absorbs most of this glucose with less than 0.5g excreted in the urine daily [13]. The 
vast majority of this is accomplished in the proximal tubule. 
 
The sodium dependent glucose transporters (SGLT), located on the apical side of the 
proximal tubule cell, are able to accumulate glucose within the cell against a 
concentration gradient by transporting glucose concurrently with sodium. A sodium 
concentration gradient is provided by a Na-K-adenosine triphosphatase (Na-
KATPase) pump located on the basolateral side that pumps sodium out of the cell. 
Glucose is then passively transported across the basolateral side of the cell via 
facilitative glucose transporters (GLUT) into the interstitium. In the early segments of 
the proximal tubule, SGLT2 on the apical membrane is coupled with GLUT2 on the 
basolateral side, and it reabsorbs up to 90% of filtered glucose under normoglycaemic 
conditions [14]. By blocking the reabsorption of glucose and sodium in the proximal 
tubule, SGLT2 inhibitors act to reduce blood glucose levels by enhancing glucose 
excretion, and promote a natriuretic and diuretic action, which should normalise the 
altered sodium handling seen in diabetes. 
 
To demonstrate the glucose reabsorption capacities of SGLT2 further, SGLT1 gene 
knockout mice show nearly 97 % reabsorption of filtered glucose compared to wild 
type mice [15]. By contrast, it has been shown in SGLT2 gene knockout animals that 
reabsorption of the filtered glucose is incomplete, ranging from 10-60% depending on 
the amount of filtered glucose. Whilst this demonstrates that SGLT1 transporters are 
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not able to completely make up for a lack of SGLT2, there is some compensatory 
uptake by SGLT1in this situation[1], which has implications for patients treated with 
SGLT2 inhibitors. In addition, a third type of sodium glucose transporter, SGLT3, has 
been identified and evaluated over the last few years. It has been recently shown to 
participate in glucose dependent sodium intake although it does not transport glucose 
[16].  
 
There has been increasing work done in recent times in the area of SGLT2 expression 
and function, which may potentially impact on the importance and efficacy of SGLT2 
inhibitors in diabetic patients. There is a tubular transport maximum for glucose 
limiting the reabsorption capacity which in diabetes is increased, suggesting there is 
increased ability to reabsorb filtered glucose [17]. This is clearly counterproductive 
for the diabetic patient, both serving to increase plasma glucose levels and exposing 
the proximal tubular cells to an increased concentration of glucose. It has become 
clear that this increase in glucose reabsorption relates at least in part to an alteration in 
SGLT2 expression on exposure to high glucose, and possibly also to a change in 
SGLT1 expression. Proximal tubular cells obtained from urine of diabetic patients 
have shown increased expression of SGLT2 [14] and studies in obese Zucker rats 
have shown that diabetes causes increased RNA expression of SGLT2 and SGLT1 in 
the kidney [18]. A variety of factors have been linked to the alteration in expression 
of SGLT1 and 2, including HNF1α and SGK1 [19] but more recently our group has 
confirmed upregulation of expression of SGLT2 when proximal tubular cells are 
exposed to transforming growth factor β (TGFβ), a pro-fibrotic cytokine [20]. 
Interleukin-6 and tumour necrosis factor-α have been shown to increase SGLT2 
expression in cultured kidney cell lines after exposure for 96-120 hours [21] and a 
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pathway for high glucose induced increased SGLT2 expression has been 
demonstrated via Protein Kinase A (PKA) and Protein Kinase C (PKC) dependent 
pathways [22, 23]. There is also evidence of interaction between the sodium glucose 
cotransporters and the renin-angiotensin-aldosterone system (RAAS). It has been 
shown in animal studies that Losartan, an angiotensin receptor blocker (ARB) reduces 
SGLT2 expression in diabetic rats on normal and high salt diets [24]. This intriguing 
connection suggests another possible mechanism for the beneficial role of ARBs in 
diabetic nephropathy.  
 
Finally, evidence also exists in regard to the effect of glucose on the expression and 
location of the facilitative glucose transporters, which usually reside in the basolateral 
membrane of the proximal tubular cell. It has been shown in diabetic rats that GLUT2 
expression increases in diabetes and translocates to the luminal surface of the 
proximal tubular cell playing a role in increased glucose reabsorption [25].  
 
Clearly, while SGLT2 is the predominant glucose transporter in the proximal tubule, 
its expression and that of the other glucose transporters can be altered in the diabetic 
milieu having implications for the efficacy of selective SGLT2 inhibitors, perhaps 
evidenced by their lack of complete glucose blockade despite increasing doses. To 
that end, there is renewed interest in dual SGLT1/SGLT2 blockade with one drug, 
LX4211 currently in clinical trials [26]. 
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2.3 SGLT2 inhibitors and the pathogenesis of diabetic nephropathy  
 
Diabetic nephropathy results from high glucose mediated inflammation and altered 
sodium handling that eventually results in fibrosis. There is both glomerular and 
tubulointerstitial damage although the decline in renal function parallels more closely 
the degree of tubulointerstitial damage [27]. High glucose is directly responsible for 
the changes seen in diabetic nephropathy and improved glycemic control has been 
demonstrated to slow the progression of the disease [28]. However, there are two 
processes that contribute to the pathology of diabetic nephropathy that may be 
expected to be altered by SGLT2 inhibitors, independent of their effect on glucose 
lowering (Figure 2.1).  
 
The proximal tubular cell secretes inflammatory molecules and growth factors in 
response to high glucose. This results in activation of an inflammatory cascade and 
recruitment of macrophages with propagation of hypertrophy and interstitial fibrosis 
[29]. The most important mediator of this pathogenesis is TGFβ which promotes 
fibrosis and epithelial to mesenchymal transdifferentiation [30]. There is a host of 
other inflammatory mediators and growth factors involved in this complex process 
[31]. It is possible that a reduction in glucose transit through the proximal tubular 
cells (PTC) may reduce PTC induced inflammation and fibrosis in diabetic 
nephropathy. Indeed, our group has shown that SGLT2 inhibition in immortalized 
proximal tubular cell lines (HK2 cells) reduced high glucose induced Toll like 
Receptor 2 and 4 as well as nuclear factor kappa B (NFκB) and activator protein 1 
(AP1) expression, which are important inflammatory and fibrotic mediators in 
diabetic nephropathy [20].   
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Another important aspect of diabetic nephropathy is hyperfiltration associated renal 
injury. Glomerular hyperfiltration associated with enhanced sodium and glucose 
reabsorption in the proximal tubule occurs quite early in the disease process [32] and 
plays an important role in diabetic nephropathy [33]. Increased proximal tubular 
sodium reabsorption results in decreased distal delivery of sodium to the macula 
densa, which regulates tubuloglomerular feedback. This also activates the renin 
angiotensin system resulting in elevated intraglomerular pressure and increased 
glomerular filtration rate (GFR) [34]. By inhibiting sodium reabsorption in the 
proximal tubule and by thereby increasing sodium delivery to the juxtaglomerular 
apparatus, it might be expected that the glomerular hyperfiltration would be reversed. 
Indeed, phlorizin, a non selective SGLT inhibitor, has been shown to abrogate the 
development of hyperfiltration in whole animal studies, and in single nephron studies, 
animals treated with phlorizin have a reduction in sodium reabsorption and 
normalisation of glomerular filtration rate, disproportionate to the improvement in 
plasma glucose [32]. This finding has been recently confirmed using a rat model and a 
selective SGLT2 inhibitor, and extended to show that the effect is sustained with 
chronic SGLT2 blockade [3]. 
 
2.4 Genetic defects in SGLT2 expression   
 
Familial renal glycosuria (FRG) has been known to exist for a long time and there are 
several genetic mutations ranging from missense and nonsense mutations to small 
deletions and splicing mutations that are known to result in loss of SGLT2 function. 
Their inheritance has variously been described as autosomal recessive [35] or co-
dominant inheritance with variable penetrance [36]. To date, 49 different SLC5A2 
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mutations have been reported in association with FRG but a recent study detailing 
FRG in 23 unrelated children that were consistent with a codominant inheritance 
pattern with incomplete penetrance has further extended the allelic heterogeneity [37]. 
The degree of glycosuria depends on the pattern of gene inheritance, with 
heterozygotes having far less glycosuria than individuals with homozygous 
inheritance, and ranges from a few grams to >120grams per day [38, 39]. This 
condition seems to be well tolerated by the individuals affected, apart from activation 
of renin angiotensin system due to volume depletion in some individuals and 
occasional aminoaciduria. The literature is consistent with FRG being a largely 
benign condition with no serious adverse consequences. 
 
However, the recent development of the Sweet pee mouse model may be cause for 
some concern. This model, which carries a nonsense mutation in the Slc5a2 gene, has 
a loss of function of the SGLT2 protein that mimics patients with similar SLC5A2 
mutations. As expected, when diabetes mellitus is induced, these mice demonstrate 
increases in glycated haemoglobin that are less than their wild type counterparts, but a 
little unexpectedly, Sweet pee mice suffer from growth retardation, increased 
infections and mortality [40]. While this might appear to be a cautionary message in 
regard to the use of SGLT2 inhibitors, it should be remembered that diabetes was 
induced with streptozotocin, which mimics a type 1 diabetic phenotype, not the type2 
diabetes for which SGLT2 inhibitors are intended. However the sweet pee model has 
no known relevance for human disease and no known similarity to SGLT2 effect. 
 
Finally, a recent study has explored the impact of common SGLT2 variants on 
glucose homeostasis in non-diabetic individuals finding alterations in glucose and 
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insulin concentrations dependent on SGLT2 activity [41]. This concept of genetic 
variability causing alterations in SGLT2 function within patients receiving SGLT2 
inhibitors opens the door for further pharmacogenomic studies to clarify the role of 
SGLT2 inhibitors in treating diabetic patients. 
 
2.5 SGLT2 inhibitors and renal endpoints 
 
There are at least 12 SGLT2 inhibitors in various stages of clinical development. 
Some of these are in Phase III trials and two drugs are awaiting approval from 
licensing authorities. The most advanced among the SGLT2 inhibitors are 
Dapagliflozin and Canagliflozin. The other prominent drugs being developed under 
this category include empagliflozin, sergliflozin, ipragliflozin, tofogliflozin and 
luseogliflozin. These drugs are attractive as antidiabetic agents because of their 
insulin independent action and a reduced incidence of hypoglycaemia. 
 
The SGLT2 inhibitors have been shown to reduce fasting plasma glucose and HbA1c 
levels in treatment naïve diabetic patients as monotherapy [12] and also as add on 
therapy to patients already on insulin [11, 42] and metformin [43, 44]. The degree of 
drop in HbA1Cc varies from 0.58 to 1% in these trials. Tighter control of diabetes has 
been shown to reduce the incidence of diabetic nephropathy on long term follow up of 
the intensive glucose control cohort in UK Prospective Diabetes Studies (UKPDS). 
Intensive blood glucose control has also been shown to reduce the incidence of 
diabetic nephropathy in a cohort of patients with type 2 diabetes over a 5-year period 
in the Action in diabetes and vascular disease: Preterax and Diamicron controlled 
evaluation trial [45].  Hence SGLT2 inhibitors should have a direct renal benefit due 
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to their glycaemic effects [28]. Ideally, hard end points of renoprotection should be 
demonstrated by longterm preservation of glomerular filtration rate (GFR) and 
prevention of albuminuria, but to date those data are not available. A non selective 
SGLT inhibitor, T-1095 has been shown to reduce HbA1C and reduce the degree of 
microalbuminuria in yellow KK mice, an obese type 2 model with insulin resistance 
[46]. Streptozotocin induced diabetic rats treated with T-1095 showed no increase in 
urinary albumin levels and kidney weight, when compared with diabetic control rats 
[47].  This drug has also been shown to preserve glomerular structure and reduce 
mesangial expansion in diabetic animals [48]. 
 
In clinical trials, dapagliflozin has shown transient decline in the GFR on initiation of 
treatment, which normalises in patients who have normal baseline renal function [49]. 
However in a 52 week placebo controlled trial in patients with moderate renal 
dysfunction (GFR >30 and <60), this initial drop remains stable without correction 
during the duration of treatment although there was improvement in albuminuria [50]. 
In a 26 week, Phase III placebo controlled trial in patients with moderate renal 
dysfunction, canagliflozin at varying doses showed mild worsening of creatinine 
levels (9% and 10% vs 4%) although the albumin creatinine ratio (ACR) and HbA1c 
showed improvement [51]. Finally, dapagliflozin has been reported to be less 
effective in lowering HbA1C in patients with a reduction in renal function as might be 
expected given that the effect of the drug requires ample GFR [50]. 
 
Further long term studies with hard renal endpoints are required to establish the renal 
benefits of SGLT2 inhibition. 
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2.5.1 Non glycaemic benefits 
 
Whilst improved glycaemic control is likely to translate into improvement in renal 
outcomes, the SGLT2 inhibitors also have a number of nonglycaemic effects that may 
contribute to renal benefit, including effects on weight, blood pressure, lipids and uric 
acid.  
 
Patients receiving SGLT2 inhibition undergo weight loss [11, 52], that initially may 
represent loss of fluid due to the drugs’ diuretic effect but in the long term is caused 
by a loss of subcutaneous fat secondary to urinary loss of calories [43]. Body weight 
loss appears to plateau after several months of treatment, perhaps due to a 
compensatory increase in calorie intake [12, 43, 53]. 
 
As outlined above, SGLT2 inhibition is likely to cause natriuresis and diuresis that 
would likely be associated with a reduction in blood pressure. SGLT2 inhibition has 
been shown to prevent blood pressure rises in diabetic rats maintained on a high salt 
diet [54] and there has been a reduction in seated systolic BP of 4.4 mm Hg and 
diastolic BP of 2.1 mm Hg among pooled data from dapagliflozin’s clinical trials, 
without any significant increase in postural hypotension [42, 43]. 
 
Canagliflozin has been noted to raise both HDL and LDL in one of the trials [44] and 
dapagliflozin has been noted to raise HDL [55]. The dual SGLT1/SGLT2 blockers, 
LX4211 has been shown to reduce triglyceride levels in a 28 day study in diabetic 
patients and may be related to an increase in glucose like peptide-1 (GLP-1) release 
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[26]. Whilst these results are interesting, they may reflect the associated weight loss 
these agents induce. 
 
Finally, dapagliflozin has been shown to reduce serum uric acid levels with no 
significant change in electrolytes [56]. This may occur due to an increase in uric acid 
excretion via one of two mechanisms: increased flux of sodium through sodium-
dependent phosphate transporters that simultaneously serve as urate transporters into 
the urine; or increased reabsorption of glucose via GLUT9 that exchanges glucose for 
uric acid [57]. Regardless, with elevated levels of uric acid being linked to 
progression of chronic kidney disease [58], reduction of levels may serve to improve 
renal outcomes in diabetic patients. 
 
2.5.2 Renal risks 
 
Most of the clinical trials show increased incidence of genital fungal infections [43], 
although urinary infections were only minimally different [42, 43] and were largely 
managed with conventional medications and did not require cessation of SGLT2 
inhibitors. Interestingly, in studies where dapagliflozin was added to metformin, there 
was no difference in incidence of urinary tract infections between the two arms [43], 
while in those patients where the drug was supplementary to insulin, there was an 
increase in infection rate [42]. This difference may reflect differences in stage of the 
disease where insulin is likely to be prescribed and at which patients are more 
vulnerable to infection. 
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Given that osmotic diuresis accompanies the glycosuria and natriuresis, there have 
always been concerns that treatment with SGLT2 inhibition may result in 
symptomatic volume depletion. Indeed, an increase in urine volume is noted with 
both with acute and chronic SGLT2 inhibition that at most represents an increase of 
400 ml/day [49]. Whilst this tends to translate into mild haematocrit increases, clinical 
signs of volume depletion are unusual and have generally only been noted among 
patients on Dapagliflozin who were also being treated with loop diuretics [49].  
 
The major concerns raised by the FDA regarding dapagliflozin, however, were the 
higher incidence of bladder and breast cancer among patients receiving this 
medication and one probable case of drug induced hepatitis [49]. The FDA has 
recommended further trials to evaluate these specific concerns before approval. 
However dapagliflozin has received a favourable decision from the Committee for 
Medicinal Products for Human Use (CHMP) of the European Medicines Agency and 
is awaiting approval. A pharmacovigilance plan for this drug will be implemented as 
part of the marketing authorisation. Canagliflozin has submitted an application for 
approval to the FDA and also to the European Medicines Agency.  
 
2.6 Conclusion 
 
The role of SGLT2 in glucose and sodium transport has increased in the last two 
years. There is increasing knowledge of this transporter and the mechanisms of 
pharmacological inhibition of both SGLT2 and SGLT1 [59]. A large amount of data 
from clinical trials is available in the public domain and the drugs will soon enter the 
pharmacological market. These trials have confirmed glycaemic benefits and minor 
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adverse effects, which were expected, based on animal studies and early clinical trials. 
However they have also brought to focus other concerns regarding malignancy and 
drug reactions. These concerns will only be allayed by longer clinical trials and post 
marketing monitoring.  
 
Most of the trials have focused on the classic outcome measures of anti diabetic 
drugs, namely improved glycaemia, weight loss, cardiovascular benefit including 
blood pressure and lipid profile. Renal disease is one of the major microvascular 
complications of diabetes and to date, while short term studies have been reassuring 
in regard to renal safety with these drugs, there has been a lack of long term data 
clarifying renal benefit. Given the glycaemic benefit of these agents and the other 
non-glycaemic effects, such as weight loss, blood pressure control and reduced uric 
acid levels, in combination with the long term effects of reduced glucose reabsorption 
through the proximal tubular cell and alteration in sodium handling, it would be 
anticipated that long term trials will yield a benefit. 
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Figure 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Potential role of SGLT2 inhibition in renoprotection 
SGLT2 inhibitors prevent increased transport of glucose through the proximal tubular 
cell and hence theoretically will prevent hypertrophy, hyperplasia with inflammation 
and eventual fibrosis. Simultaneously, they reduce the proximal tubular fractional 
reabsorption of sodium with increased distal delivery of sodium and chloride to the 
macula densa resulting in activation of tubuloglomerular feedback (TGF) with 
consequent reduction in single nephron glomerular filtration rate (SNGFR) and 
prevention of hyperfiltration injury. 
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Chapter 3: Empagliflozin for the treatment of Type 2 
diabetes. 
 
Gangadharan Komala M, Mather A. 
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Abstract 
 
Diabetes and its complications account for a significant healthcare burden. There is 
increasing prevalence of diabetes and newer drugs are being investigated to improve 
outcomes. Sodium glucose cotransporter inhibitors (SGLT2 inhibitors) are a newer 
class of medications, which prevent renal reabsorption of glucose and hence help in 
glycaemic control without significant risk of hypoglycaemia. Two drugs, namely 
dapagliflozin and canagliflozin have gained approval and empagliflozin is one of the 
advanced agents of this class. Early trials with empagliflozin have shown a stable 
pharmacokinetic profile and pharmacodynamic effects with significant SGLT2 
selectivity. Clinical trials have shown improvement in glycaemic control and other 
benefits including weight loss and lowering of blood pressure. Ongoing trials and 
surveillance will provide answers about cardiovascular benefits, risk of osteoporosis 
and cancer. 
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3.1 Background 
 
Diabetes mellitus is a chronic disease with multisystem involvement leading to 
microvascular and macrovascular complications. The current worldwide prevalence 
of diabetes is estimated to be 6.4 % and expected to climb to 7.7 % by 2030 [60]. 
Type II diabetes constitutes more than 90 % of overall prevalence. The treatment of 
diabetes has come a long way over the last few decades with a range of medications 
including insulin, insulin secretagogues and drugs that increase insulin sensitivity. 
These medications have increased the survival of patients with diabetes over the years 
in developed countries. However the global mortality due to diabetes has increased by 
20 % since 1990 [61].  Moreover the prevalence of microvascular complications like 
diabetic kidney disease has not improved over the last decade despite an increasing 
use of anti diabetic medication [62]. With the looming prospect of increasing 
worldwide prevalence of diabetes, it is important to identify newer drugs that improve 
management of diabetes and reduce the morbidity and mortality associated with this.  
This review discusses a new class of agents designed for the treatment of diabetes, the 
sodium glucose cotransporter inhibitors, with particular reference to empagliflozin, 
one of its members. 
 
3.2 Sodium glucose cotransporter inhibitors 
 
Most of the glucose filtered by the glomeruli is reabsorbed by two glucose 
transporters located in the renal proximal tubule, namely sodium glucose 
cotransporter 2 (SGLT2) and sodium glucose cotransporter 1 (SGLT1). The 
combination of these two transporters reabsorbs the majority of a large load of filtered 
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glucose, in the order of 180g glucose/day, such that less than 0.5 g/day of glucose is 
lost in the urine [13]. SGLT2 is the primary glucose transporter [1], accounting for 
90% of glucose reabsorption, and only becomes saturated when the glucose 
concentration increases above 35 mM [63]. SGLT1 is present in the gut and in the 
kidneys and is primarily involved in glucose reabsorption from the gut. It plays a 
minor role in glucose reabsorption in the kidney. Sodium glucose cotransporter 
inhibitors (SGLT2i) are newer agents in the anti-diabetic armamentarium that act by 
blocking this glucose reabsorption in the proximal tubule, thereby lowering plasma 
glucose concentrations by increasing glycosuria. Phlorizin was the first SGLT 
inhibitor, which was extracted from the bark of the apple tree in 1835. Its ability to 
induce glycosuria was noted nearly 50 years after its discovery. Phlorizin is a non-
specific SGLT inhibitor and blocks both SGLT2 and SGLT1 and has poor oral 
absorption. Hence it is not suitable for preventing glucose reabsorption due to 
associated gastrointestinal side effects, namely diarrhea [64]. The current focus has 
been on developing phlorizin analogues, which selectively inhibit SGLT2 mediated 
glucose transport at the renal proximal tubule. However it is to be noted that dual 
blockade of SGLT1 and SGLT2 prevents renal and intestinal glucose absorption and 
hence dual blockade agents, which produce lesser gastrointestinal side effects are also 
under development [65]. The most advanced selective SGLT2 inhibitors are 
dapagliflozin, canagliflozin and empagliflozin.  Canagliflozin and dapagliflozin has 
been approved by FDA and the European Drugs agency for management of type 2 
diabetes. Both drugs have also received approval from the Therapeutic Goods 
Administration in Australia.  
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A recent meta analysis incorporating available clinical data on SGLT2i shows 
consistent glycaemic benefits from the use of SGLT2i with improvement in HbA1c 
by up to 0.66% [66]. These agents have been shown to improve HbA1c significantly 
as single agent and as add on agent to other therapy including metformin and insulin. 
This analysis also shows improvement in systolic BP by 3.77 mm Hg and weight loss 
of 1.77 kg compared to placebo. This lowering of blood pressure is likely to be 
contributed by osmotic diuresis associated with glycosuria. There are other factors 
including renin angiotensin aldosterone inhibition due to increased sodium delivery to 
the juxtaglomerular apparatus [67]. Similarly, weight loss is due to a combination of 
diuresis and fat reduction and has been noted to be sustained during the course of 
clinical trials [43]. The SGLT2i are most effective in patients with eGFR> 60 
ml/minute/1.73m2 with decreasing efficacy as the kidney function is reduced. This is 
due to the poor filtration of the drug into the proximal tubule as the GFR worsens. It 
has been also noted that the incidence of urinary tract and genital infections were 
higher in diabetic patients treated with SGLT2i [66]. The exact cause for the 
increased incidence of urinary tract infections and genital infections have not been 
evaluated although it is presumed to be likely due to the increased glucose in the 
urine. The trials with dapagliflozin have also raised safety concerns with inexplicable, 
although marginally higher incidence of bladder and breast cancers in the 
dapagliflozin treated patients [68].  
  
Hence these drugs have established themselves as good oral agents for diabetes with 
demonstrated benefits in reducing HbA1c in addition to other benefits including 
weight loss and improving blood pressure. The dapagliflozin trials have not shown an 
increase in cardiovascular events when compared to placebo [69]. However the 
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incidence of major adverse cardiovascular events (MACE-plus) defined as 
cardiovascular death, non fatal myocardial infarction, non fatal stroke and 
hospitalization for unstable angina was increased in the first 30 days after initiation of 
treatment with canagliflozin [70]. The incidence of MACE-plus episodes was similar 
to placebo after the first 30 days. The canagliflozin trials have shown a dose 
dependent increase in LDL cholesterol [70]. However it is unclear if they will have an 
impact on the cardiovascular risk in diabetic patients in the long term. Bone safety is 
another area of concern regarding these agents. There was an increased incidence of 
fractures in patients treated with canagliflozin [70]. Treatment with dapagliflozin was 
noted to increase fracture incidence in patients with moderate renal dysfunction [71]. 
The pooled placebo controlled trials of canagliflozin have shown minimal increases in 
serum calcium of 0.6-1.1% and serum phosphorus of 5.1 % with 300 mg 
canagliflozin. In patients with moderate renal impairment mean serum calcium and 
phosphorus increased by 1.3 and 7.6% with canagliflozin at a dose of 300 mg. Mean 
serum PTH declined by 16.1% compared to placebo and there were moderate increase 
in 25-OH-vitamin D and slight decrease in 1,25-OH-vitamin D although these 
changes were not statistically significant. However bone turnover markers were 
significantly increased with canagliflozin compared to placebo. The total hipbone 
mineral density (BMD) showed a significant decline of 0.4 and 0.6 % with 100 mg 
and 300 mg of canagliflozin respectively when compared to placebo. However BMD 
changes were not significant at the lumbar spine and 1/3 radius. The incidence of 
fractures seems to be increased in patients on canagliflozin, especially low trauma and 
upper extremity fractures although they do not reach statistical significance. Results 
from ongoing longer duration studies are awaited before the effects of canagliflozin 
on bone health can be fully determined. The proposed mechanisms for increased bone 
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resorption include weight loss without an increase in physical activity although 
dapagliflozin showed no increase in fractures with a similar degree of weight loss in 
patients with normal renal function. There has been no increase in urinary calcium 
excretion with only small increases in urinary phosphate excretion in 12-week studies. 
Hence the etiology of increased bone turnover, low BMD and increased risk of 
fractures remains to be evaluated. One patient was noted to have probable drug 
induced liver injury (DILI) in an analysis of all the dapagliflozin trials presented to 
the FDA for approval although canagliflozin does not seem to have had any episode 
of DILI [69, 70]. These trials have also shown a small decrease in eGFR after 
initiation of SGLT2i although this seems to correct after discontinuation of the 
medication.  
 
SGLT2i have been shown to reduce glomerular hyperfiltration very early after 
initiation and this was expected to improve the incidence of diabetic nephropathy. 
However it is now emerging that the renal benefits are commensurate with improved 
glycaemia rather than the ability of SGLT2i to reduce hyperfiltration injury[72]. It has 
been demonstrated that high glucose mediated toxicity to the β cells of pancreas is 
ameliorated by early initiation of SGLT2i resulting in preservation of these cells [53]. 
Hence the beneficial effects of SGLT2i in preventing diabetic nephropathy and 
improved diabetic control seem to stem from improved glycaemia rather than any 
additional physiological benefit. This could be true for all other complications of 
diabetes.  
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3.3 Pharmacokinetics, pharmacodynamics, potency and selectivity of 
empagliflozin   
 
The pharmacokinetics of empagliflozin is similar following single dose and multiple 
doses at steady state. Peak levels are attained 1.5-3 hours after oral administration and 
half-life ranges from 10-19 hours. This pattern has been suggested to signify linear 
pharmacokinetics. Population pharmacokinetics were studied in 974 patients with 
Type 2 diabetes using pooled data from five randomized controlled trials with 
multiple oral doses of empagliflozin [73]. The steady state exposure was shown to be 
dependent on weight with no relation to sex or race demonstrated. Additionally, 
empagliflozin pharmacodynamics were studied in 48 healthy male Japanese patients 
[74]. This study demonstrated increased urinary glucose excretion between 5-7 hours 
after drug administration with the degree of glucose excretion being proportional to 
the dose. Most of the drug effect was attained by 24 hours, although at a higher dose 
of 100 mg the glycosuric effect was observed for up to 72 hours. It is to be noted that 
the maximum 24 hour urinary glucose excretion attained by empagliflozin is 
approximately 89 g in diabetic patients which is about half of the total glucose filtered 
into the proximal tubule [75]. This finding is similar to trials with other SGLT2i 
wherein filtered glucose is only partially prevented from being reabsorbed. There are 
multiple possible reasons that have been proposed for this including competitive 
antagonism with high glucose for drug binding to SGLT2, upregulation of other 
transporters which compensate for SGLT2 inhibition and high plasma protein binding 
which prevents drug delivery to the proximal tubule [76]. 
  
	 31 
Empagliflozin has been shown in in vitro studies to inhibit the uptake of [14C]- alpha 
methyl glucopyranoside (AMG) via hSGLT2 in a dose dependent manner with an 
IC50 of 3.1nM [77]. This was similar to other C-glucoside SGLT2 inhibitors namely 
dapagliflozin, canagliflozin, ipragliflozin and tofogliflozin. Empagliflozin however 
displayed the highest selectivity for SGLT2 over SGLT1 among all C-glucoside 
SGLT2 inhibitors. Empagliflozin displayed high affinity for SGLT2 with a Kd of 57 ± 
37 nM in the absence of glucose. However the affinity decreased to a mean Kd of 194 
± 99 nM in the presence of glucose at a concentration of 20 mM. This displays the 
competitive nature of SGLT2 binding between empagliflozin and glucose. The half 
life of the empagliflozin and SGLT2 bond was shown to be 59 ± 5 minutes, which 
was unaffected by high glucose concentration. This extended binding could explain 
the duration of action of empagliflozin that extends beyond the point of falling serum 
concentration. 
  
No significant interaction was noted when empagliflozin was coadministered with 
warfarin [78], verapamil, ramipril, digoxin [79] or ethinyl estradiol and levonorgestrol 
[80] suggesting that empagliflozin does not interfere with coadministration of other 
common medications. 
   
Empagliflozin is eliminated by glucuronidation and nearly 19% is excreted 
unchanged in the urine [81]. Empagliflozin showed increased absorption and higher 
peak levels along with increased area under the curve in patients with hepatic 
impairment [82]. These changes in pharmacokinetic parameters were proportional to 
the degree of hepatic impairment. However the half-life was unaffected and the 
adverse effect profile was similar among all groups. In this study, a dose of 50 mg 
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was well tolerated by all groups suggesting that dose modification may not be 
necessary in patients with hepatic impairment. It has been proposed by the study 
authors that the increased peak levels in hepatic impairment are due to reduced 
hepatic enzyme activity suggesting reduced first pass metabolism in hepatic 
impairment. Renal clearance of unchanged drug is an important pathway for drug 
elimination. Moreover, the pharmacodynamics of empagliflozin depends on renal 
function, as the site of action is the renal proximal tubules. As expected, 
empagliflozin was shown to have slower absorption in patients with renal dysfunction 
[81], the exact mechanism for which has not been clearly elucidated However, the 
clearance rate was reduced and the area under the curve was increased with increasing 
renal dysfunction. The fractional excretion of empagliflozin also declined with 
declining renal function from 16.1 % in patients with normal renal function to 0.3 % 
in patients with end stage kidney disease (ESKD). A change in pharmacodynamics 
was noted in parallel with progressive renal impairment. The urinary glucose 
excretion increased 97.64 g/24 hours from baseline in patients with normal renal 
function with empagliflozin, whereas there was an increase of just 0.78 g/24 hours 
from baseline in patients with ESRD. 
  
In summary, empagliflozin has a peak onset of action at 5-7 hours after oral 
administration with a dose dependent glycosuric response. There is no significant 
drug interaction with the common medications that have been examined. It displays 
significant selectivity for SGLT2 in comparison to other SGLTs but its affinity is 
affected by the glucose concentration. Empagliflozin pharmacokinetics is affected by 
hepatic and renal impairment, although dose modification has not been recommended 
	 33 
based on available evidence [81]. However progressive renal dysfunction impacts on 
the clinical efficacy of empagliflozin due to its mode of action.  
 
3.4 Clinical efficacy of empagliflozin  
 
There have been five published randomised clinical trials on empagliflozin (Table 1). 
Empagliflozin has been shown to be beneficial in improving glycaemic control as a 
single agent. In a Phase II trial, empagliflozin has shown reduction in HbA1c by 0.5-
0.7% with increasing doses from 5-25 mg qd, compared to placebo in patients with 
Type 2 diabetes [83]. These results were similar to open label metformin at a dose of 
1000-2000 mg daily. Similarly, in a recent Phase III trial in patients with type 2 
diabetes, compared with placebo, adjusted mean differences from baseline HbA1c at 
week 24 were 0·74% at a daily dose of 10 mg and 0·85% at a dose of 25 mg similar 
to 0·73% seen with sitagliptin at a dose of 100 mg [84].  
 
Empagliflozin has also been shown to have cumulative glycaemic benefits as add on 
therapy. Empagliflozin, as an add on therapy to metformin, in patients with mild 
hyperglycaemia, has been shown to improve HbA1c by 0.24-0.71 % compared with 
placebo after 12 weeks of treatment[85]. In the EMPA-REG METSU trial, a Phase III 
randomised, double blinded, placebo controlled trial in patients with suboptimal 
control of type 2 diabetes on sulfonylureas and metformin, empagliflozin, as an add 
on agent, was able to reduce HbA1c significantly by up to 0.82 % at a dose of 10 mg 
and 0.77% at a dose of 25 mg compared to 0.17% with placebo after 24 weeks of 
treatment, showing the additive benefits of this medication [86].  Similarly, 
empagliflozin was beneficial as an add on agent to insulin in a double blinded study 
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with a significant reduction in HbA1c as early as 18 weeks after initiation of this 
medication, when compared to placebo. In addition it was also shown to reduce 
insulin requirements by 6.66 units, compared to placebo after 78 weeks of treatment 
[87]. Empagliflozin, as an add on agent to pioglitazone with or without metformin, 
has also been shown in a phase III trial to improve HbA1c significantly after 24 
weeks of treatment [88].  
  
In addition to improved glycaemic control, empagliflozin has also been shown to 
induce weight loss and improve blood pressure. Empagliflozin as an add on to insulin 
therapy was able to reduce body weight by up to 2.2 kg and improve systolic blood 
pressure by up to 4 mm Hg after 78 weeks of treatment at a dose of 10 mg daily [87]. 
A pooled analysis of four randomised, placebo controlled Phase III trials with 
empagliflozin as either a single agent or as add on therapy to sulphonylureas, 
metformin or pioglitazone has shown additional improvements in cardiovascular risk 
factors [89]. In addition to an improvement in HbA1c by 0.68%, weight loss of 2.25 
kg and an improvement in both systolic and diastolic BP, empagliflozin also increased 
HDL cholesterol by 0.07 mmol/L, LDL cholesterol by 0.1 mmol/L, reduced 
triglycerides by 0.11 mmol/L and serum uric acid by 29 mmol/L after 24 weeks of 
treatment. 
  
Empagliflozin and other SGLT2i act in an insulin independent manner and hence 
would be expected to provide glycaemic control irrespective of the stage of type 2 
diabetes. This was indeed shown in a recent study where oral glucose tolerance of 
empagliflozin remained high even at 27 weeks of age in Zucker diabetic fatty rats. 
This was comparable to metformin and significantly higher than that of glipizide [90]. 
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 SGLT2i induce glycosuria and this can have physiological consequences. In a small 
study of 66 patients with type 2 diabetes, it was shown that empagliflozin increased 
endogenous glucose production in the fasting state to match glucose loss in the urine. 
However the systemic exposure to high glucose was reduced after a meal in spite of 
an increase in endogenous glucose production. Moreover it was noted that glucose 
oxidation was reduced and lipid oxidation increased suggesting a shift in substrate 
utilization from glucose to lipids [91]. This could be one of the reasons for the long-
term weight loss associated with SGLT2i usage. 
   
Empagliflozin and other SGLT2i act on renal proximal tubules and have reduced 
efficacy with worsening renal function. In a Phase III study in patients with mild 
(eGFR 60-90) and moderate  (eGFR 30-60) renal dysfunction, it was noted that after 
24 weeks of treatment, HbA1c was reduced by 0.68 % and 0.42% in patients with 
mild and moderate renal dysfunction respectively. This shows the even though there 
is a reduction in clinical efficacy of empagliflozin with renal dysfunction, it is still 
able to show benefits compared to untreated patients [92].  
 
3.5 Safety profile and adverse effects 
 
3.5.1 Urinary complications 
 
The adverse effect profile of empagliflozin is similar to other drugs in this category. 
The incidence of genital infections has been shown to be increased when compared to 
placebo in a pooled analysis of four major phase III clinical trials. However the 
incidence of urinary tract infections has not been shown to be substantially increased 
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[93]. Empagliflozin has also been shown to induce frequent daytime urination in some 
studies [83]. 
 
3.5.2 Metabolic adverse effects 
 
Empagliflozin has not been found to increase the incidence of hypoglycemia in a 
phase III trial comparing empagliflozin as add on therapy to pioglitazone or 
pioglitazone with metformin [94]. Similar to other SGLT2i, empagliflozin has been 
shown to cause a small drop in eGFR in a randomized open label extension study with 
empagliflozin or metformin as monotherapy and empagliflozin or sitagliptin as add on 
therapy to metformin, although this has been reported to be small and comparable 
among all groups [95]. Volume depletion is again a class effect and has been shown 
to develop in 3% of patients on a dose of 10 mg or 25 mg of empagliflozin during a 
52 week Phase II trial in Japanese patients with type 2 diabetes [96]. 
 
3.5.3 Cardiovascular adverse effects 
 
Cardiovascular safety is an important consideration for all new drugs especially with 
adverse outcomes associated with anti diabetic medication previously. No significant 
adverse cardiovascular outcomes have been noted in all the published trials. However 
these were not dedicated to study cardiovascular outcomes or were powered to do so. 
Currently a Phase III multicenter, randomised double blind trial (NCT01131676) is 
underway to look at the cardiovascular outcomes of empagliflozin 10 and 25 mg 
versus usual care in patients with type 2 diabetes and high cardiovascular risk [97]. A 
number of drugs can cause QT interval prolongation and hence have arrhythmogenic 
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potential. Empagliflozin has not been shown to increase the QT interval in a 
randomised, placebo controlled, single dose, double blinded, five period cross over 
study in thirty healthy volunteers [98]. It has also been noted in a randomised open 
label study that empagliflozin has not shown any changes in magnesium or potassium 
levels [99]. However the long tem cardiovascular safety outcomes will depend on the 
results from the ongoing trials and post marketing monitoring after empagliflozin 
gains approval. 
 
3.5.4 Malignancy and hepatic complications 
 
Clinical trials with dapagliflozin have raised concerns regarding an unexplained 
increase in the incidence of prostate and breast malignancy and drug induced liver 
injury. No clinical data is currently available on the incidence of these complications 
with empagliflozin. However the large-scale clinical trials currently being conducted 
will tell us about these specific outcomes. 
 
3.6 Conclusion 
 
Empagliflozin has been shown to be effective in improving glycaemic control in type 
2 diabetes with significant improvement in fasting glucose and HbA1c. This has been 
attained either as a single agent or as an add on treatment to other agents including 
metformin, sulphonylureas and insulin. A single daily dose has been found to be 
effective with the drug efficacy increasing with escalating dose strengths with the 
most commonly tested doses being 10 mg and 25 mg.  
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In short term studies it appears safe with low risk of hypoglycaemia although genital 
infections are increased similar to other agents of this class. Long-term outcomes 
including cardiovascular risk or benefit and other possible adverse effects await 
evaluation with ongoing studies likely to shed more light.  
 
3.7 Expert opinion 
 
Empagliflozin holds potential as an anti diabetic agent and we expect it to be 
approved and successfully added to the growing number of SGLT2i. It has a long 
duration of action and hence will improve patient compliance, as only a single daily 
dose is required. The short-term studies have shown improvement in cardiovascular 
risk factors, namely lowering of systolic BP and weight loss. However, it remains to 
be seen if this converts into improvement in hard clinical endpoints namely reduction 
in cardiovascular mortality and morbidity. Another area of ongoing research is this 
agent’s potential to reduce microvascular complications, especially nephropathy in 
view of its unique mechanism of action. Empagliflozin has been associated with a 
reduction in GFR, which may reflect a reduction in glomerular hyperfiltration. 
However it remains to be seen if it has any independent renoprotective benefits or 
indeed harm. Its use is limited to patients with reasonably preserved renal function 
and has been shown to retain clinical efficacy till a GFR of 30 ml/minute, becoming 
ineffective with further reduction in the glomerular filtration rate.  
 
In our opinion, SGLT2i as a class are a welcome addition to the anti diabetic 
armamentarium although their long term risks and benefits have not yet been fully 
elucidated. Cardiovascular outcomes may not necessarily improve with significant 
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lowering of HbA1c and very tight blood sugar control may indeed be associated with 
increased mortality [100] or may not have any demonstrable cardiovascular benefit  
[101].  The cardiovascular outcomes of anti diabetic drugs became important after a 
meta analysis on rosiglitazone showed significant adverse cardiovascular outcomes 
[102]. However the RECORD study has shown that although risk of heart failure was 
increased, rosiglitazone did not increase the risk of major adverse cardiovascular 
events [103] with the FDA lifting restrictions on his medication. It has been shown 
recently that saxagliptin increases risk of hospitalisation for heart failure without an 
increased risk of mortality [104]. This was not evident in pre approval trials. Hence it 
is important to have dedicated trials designed and powered to look at the 
cardiovascular outcomes rather than use results from pooled data from a number of 
trials, as they may not provide answers due to study heterogeneity.  
 
Empagliflozin is the latest in this class to attempt FDA approval and it is likely that 
this drug will have a similar role to play as its counterparts. Like dapagliflozin and 
canagliflozin, it has been shown to be an effective single or add-on agent for the 
treatment of type 2 diabetes with a low risk of hypoglycaemia and is associated with a 
positive effect on cardiovascular risk factors. It too will need longer studies to better 
understand its place in the growing number of options available for the management 
of type 2 diabetes but it seems likely that it will contribute to better management of 
the diabetic patient in the future. However it has received a significant setback after 
the FDA recently rejected its new drug application citing deficiencies in its 
manufacturing base at Ingelheim. Hence Boehringer Ingelheim and Eli Lilly will have 
to invest significantly to correct these deficiencies and reapply for FDA approval. 
This information became available in a press release by Boehringer Ingelheim and Eli 
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Lilly on the 5th of March 2014. Hence its further development and approval depends 
on the rectification of the deficiencies that were identified and may delay the 
reapplication. 
 
3.8 Five-year review 
 
Empagliflozin will clearly be a significant anti-diabetic drug. In the next five years it 
has the potential to be used as a single agent or as an additional agent in the 
management of diabetes. However as mentioned earlier, the future of the drug 
depends on the outcome of corrective measures that are taken by the manufacturer in 
response to the complete response letter from the FDA.  If approved, we expect its use 
to be most significant in patients with early type 2 diabetes, especially before the 
onset of any degree of renal dysfunction. It may have a role in obese patients with 
type 2 diabetes due to the ability of SGLT2i to induce weight loss. The cardiovascular 
effects both related to and independent of glycaemic benefits will be evident from 
current trials. It will especially be interesting to look at the outcomes of adding 
empagliflozin and other SGLT2i to the usual list of cardiovascular medications 
including angiotensin converting enzyme inhibitors, angiotensin receptor blockers and 
diuretics as it is expected to increase the risk of hypotension. The risk of mycotic 
genital infections will also determine physician choice and will require strict 
compliance with genital hygiene by patients. We expect answers to all these questions 
in the next five years.  
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3.9 Key issues 
• SGLT2i are newer anti diabetic agents 
• Phase III trials have shown glycaemic benefits, improvement in blood pressure 
and weight loss 
• Short term trials reveal no significant safety concerns although genital fungal 
infections remains a concern  
• Cardiovascular outcomes, risk of cancer and effects on bone morphology 
remain to be answered  
• US FDA has rejected empagliflozin new drug application based on 
deficiencies at its main manufacturing facility 
• The success of empagliflozin depends on correction of deficiencies identified 
by the FDA and successful reapplication 
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Table 3.1 
Published randomised trials of Empagliflozin 
Study Year Number of 
patients 
Duration and  
Study population 
Groups  Mean change from baseline 
      HbA1c 
(%) 
FPG1 
(mg/dl) 
Weight SBP3 DBP4 
Rosenstock 
et al ★ 
2013 495 12 week study of patients 
with Type 2 diabetes who 
were on Metformin with 
inadequate diabetic 
control 
Empa 1 mg daily -0.09 -2 -1.6 -2.17 ± 
12.11 
-0.06 ± 
7.47 
Empa 5 mg daily -0.23 -16 -2.3 -3.03 ± 
14.58 
-0.75 ± 
8.41 
Empa 10 mg daily -0.56 -22 -2.7 -4.39 ± 
13.09 
-1.70 ± 
7.5 
Empa 25 mg daily -0.55 -27 -2.6 -8.51 ± -4.16 ± 
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12.82 8.76 
Empa 50 mg daily -0.49 -28 -2.9 -3.16 ± 
15.26 
-1.99 ± 
7.57 
Sitagliptin 100 mg 
daily 
-0.45 -13 -0.8 -1.79  ± 
11.65 
-0.35 ± 
9.35 
Placebo 0.15 5 -1.2 -2.23 ± 
14.84 
-1.01 ± 
8.27 
      FPG 
(mmol/L) 
   
Kovacs et 
al ★★ 
2013 498 24 weeks 
Patients with Type 2 
diabetes with 
7%<HbA1c<10% on 
pioglitazone ± metformin 
Empa 10 mg daily -0.59 ± 
0.07 
-0.94 ± 
0.15 
-1.62 ± 
0.21 
-3.1 ± 
0.9 
-1.5 ± 
0.5 
Empa 25 mg daily -0.72 ± 
0.07 
-1.22 ± 
0.14 
-1.47 ± 
0.21 
-4.0 ± 
0.8 
-2.2 ± 
0.5 
Placebo -0.11 ± -0.36 ± 0.34 ± 0.7 ± 0.3 ± 0.5 
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0.07 0.14 0.21 0.9 
      FPG 
(mg/dl) 
   
Ferranini et 
al ¶ 
2013 659 78 week open label 
extension study of two 12 
weeks blinded trials of 
empagliflozin as 
monotherapy and add on 
to metformin with open 
label comparators namely 
metformin and sitagliptin 
added on to metformin 
Empa 10 mg daily -0.34 -30 -2.2 0.1 -1.6 
Empa 10 mg daily 
(add on to metformin) 
-0.34 -21 -3.1 -3.3 -0.9 
Empa 25 mg daily -0.47 -28 -2.6 -1.7 -2.2 
Empa 25 mg daily 
(add on to metformin) 
-0.63 -32 -4 -3 -2 
Metformin -0.56 -26 -1.3 2 -0.6 
Sitagliptin plus 
metformin 
-0.4 -16 -0.4 1.8 1.2 
      FPG 
(mmol/L) 
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Ferranini et 
al λ 
2013 408 12 week study of type 2 
diabetic patients who are 
treatment naïve or 
included after a four 
week wash out period 
Empa 5 mg -0.4 -1.29 -1.81   
Empa 10 mg daily -0.5 -1.61 -2.33   
Empa 25 mg daily -0.6 -1.72 -2.03   
Metformin -0.7 -1.66 -1.32   
Placebo 0.1 0.04 -0.75   
      MDG2 
(mmol/L) 
   
Haring et al 
Ψ 
2013 666 24 week study of type 2 
diabetic patients on 
metformin and 
sulfonylureas with 
7%<HbA1c<10% 
Empa 10 mg daily -0.77 -1.05 -2.39 -3.5 -2.1 
Empa 25 mg daily -0.82 -1.14 -2.16 -4.1 -2.2 
Placebo -0.15 0.03 -0.39 -1.4 -1.8 
1Fasting plasma glucose, 2 Mean daily glucose, 3 Systolic blood pressure, 4 Diastolic blood pressure 
★     Significant results noted in HbA1c, FPG and body weight in all groups except with Empagliflozin 1 mg 
★★  Clinically significant results in all parameters in all dose groups of empagliflozin 
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¶       Clinically significant results in all parameters obtained at 12 weeks and were maintained after 78 weeks of extension, except  
          improvement in blood pressure with empagliflozin 10 mg 
λ       Clinically significant results with empagliflozin. Metformin not included in primary analysis and compared with placebo separately. 
Ψ      Significant results in all parameters except DBP  
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Chapter 4: Inhibition of kidney proximal tubular glucose 
reabsorption does not prevent against diabetic nephropathy 
in type 1 diabetic eNOS knockout mice. 
 
Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather 
A, Shen S, Pollock CA, Panchapakesan U. 
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Abstract  
 
Background and Objective 
Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in 
the kidney. SGLT2 inhibition results in glycosuria and improved glycaemic control. 
Drugs inhibiting this transporter have recently been approved for clinical use and 
have been suggested to have potential renoprotective benefits by limiting 
glycotoxicity in the proximal tubule. We aimed to determine the renoprotective 
benefits of empagliflozin, an SGLT2i, independent of its glucose lowering effect.  
 
Research Design and Methods 
We induced diabetes using a low dose streptozotocin protocol in 7-8 week old 
endothelial nitric oxide (eNOS) synthase knockout mice. We measured fasting blood 
glucose on a monthly basis, terminal urinary albumin/creatinine ratio. Renal 
histology was assessed for inflammatory and fibrotic changes. Renal cortical mRNA 
transcription of inflammatory and profibrotic cytokines, glucose transporters and 
protein expression of SGLT2 and GLUT1 were determined.  Outcomes were 
compared to diabetic animals receiving the angiotensin receptor blocker telmisartan 
(current best practice).  
 
Results 
Diabetic mice had high matched blood glucose levels. Empagliflozin did not 
attenuate diabetes-induced albuminuria, unlike telmisartan. Empagliflozin did not 
improve glomerulosclerosis, tubular atrophy, tubulointerstitial inflammation or 
fibrosis, while telmisartan attenuated these. Empagliflozin did not modify tubular 
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toll-like receptor-2 expression in diabetic mice. Empagliflozin did not reduce the 
upregulation of macrophage chemoattractant protein-1 (MCP-1), transforming 
growth factor β1 and fibronectin mRNA observed in the diabetic animals, while 
telmisartan decreased transcription of MCP-1 and fibronectin. Empagliflozin 
increased GLUT1 mRNA expression and telmisartan increased SGLT2 mRNA 
expression in comparison to untreated diabetic mice. However no significant 
difference was found in protein expression of GLUT1 or SGLT2 among the different 
groups.  
 
Conclusion 
Hence SGLT2 inhibition does not have renoprotective benefits independent of 
glucose lowering.  
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4.1 Introduction 
 
Diabetic nephropathy is the commonest cause of chronic kidney disease worldwide 
[105]. Current best practice in the management of diabetic nephropathy involves 
tight glycaemic and blood pressure control, which includes specific blockade of the 
renin, angiotensin aldosterone systems [106, 107]. Although treatment options for 
patients have expanded in recent years, this has not translated to a reduction in the 
incidence of diabetic nephropathy [62]. Hence there is a need for novel agents that 
confer renoprotection.  
       
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are novel diabetic agents that 
block glucose entry into the kidney proximal tubular cell (PTC), resulting in 
glycosuria and lowering of blood glucose levels and have the added advantage of 
not inducing weight gain or hypoglycaemia [108, 109].  
       
SGLTs are located on the luminal aspect of the proximal tubule (PT) and able to 
transport sodium and glucose from the ultrafiltrate into the cell due to a sodium 
concentration gradient, generated by the basolateral Na, K-ATPase pump [110]. 
Sodium glucose cotransporter 2 (SGLT2) is the major luminal glucose transporter 
located in the S1 and S2 segments of the PT, whilst sodium glucose cotransporter 1 
(SGLT1) in the S3 segment contributes to less than 10% of total luminal glucose 
transport [19]. On the basolateral side of the cell, glucose is then passively 
transported via facilitative glucose transporters (GLUTs) into the vasculature. In the 
early segments of the kidney PT, SGLT2 on the apical membrane is coupled with 
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GLUT2 on the basolateral side and together they reabsorb upto 90% of filtered 
glucose under normoglycaemic conditions [19]. 
 
Hyperglycaemia induces activation of various pathways, which stimulates the 
production of proinflammatory and profibrotic cytokines relevant in diabetic 
nephropathy including TGFβ. The effects of high glucose are predominantly 
mediated through the hypertrophic and profibrotic cytokine, TGFβ which is 
overexpressed in diabetic nephropathy [111]. There is clear evidence of the 
damaging effects of TGFβ on PTC growth and function. [112-114] We and others 
have also shown evidence for TGFβ induced activation of the innate immunity 
pathway in diabetic nephropathy, in particular Toll like receptor 2 (TLR2) and its 
endogenous ligand High Mobility Group Box 1 (HMGB1) [115, 116]. We have 
previously defined the effects of high glucose in mediating inflammatory and 
profibrotic effects in the PTC [117, 118] and the specific effects of increased PTC 
sodium transport in early diabetes. [119, 120] Hence it is well established that high 
intracellular glucose alters intracellular metabolism and promotes inflammatory and 
profibrotic cytokines resulting in the development of diabetic nephropathy [114, 
117, 121]. 
     
We have previously shown using human kidney PTC in vitro that empagliflozin, an 
SGLT2i (provided by Boehringer Ingelheim, Germany), was able to reduce high 
glucose induced tubular expression of inflammatory and fibrotic markers. In the 
short term, this occurred without a compensatory increase in SGLT1 or GLUT2 
expression [122]. 
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This provided proof of concept to extend these studies to a validated small animal 
model of diabetic nephropathy. An important aspect of our experimental design 
was to match glucose levels in all diabetic groups, so that any observed renal 
outcomes could be interpreted independent of the glucose lowering effect of 
empagliflozin, which has confounded the interpretation of previous studies to date. 
This was achieved by using a 5 day low dose protocol of intraperitoneal 
streptozotocin to induce diabetes [123] and long acting insulin in the diabetic mice 
to match glucose levels among all the experimental limbs. 
 
  4.2 Materials and methods 
 
4.2.1 Animal model  
 
Male eNOS knockout mice on a C57BL/6 background were purchased from 
Jackson laboratory, USA. Mice were housed singly in filter top cages in a pathogen 
free facility and had free access to standard chow and drinking water. Diabetes was 
induced by a low-dose streptozotocin (STZ) protocol. Mice received intraperitoneal 
injections of STZ (55 mg/kg daily for 5 days) at 7 - 8 weeks of age. Control mice 
received citrate buffer injections (pH 4.5). Blood glucose was tested using a 
glucometer (Accuchek Nano, Roche) two weeks after STZ through tail vein blood 
collection. Diabetes was defined by blood glucose greater than 16 mmol/L after a 
six-hour daytime fast. Mice with levels below 16 mmol/L were excluded from the 
study. Fasting blood glucose levels were measured monthly. Long acting insulin  
(Insulin Glargine, Sanofi Aventis, Australia) was initiated as required from 10 
weeks of age and was administered thrice weekly if the blood sugar exceeded 28 
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mmol/L or if they had lost weight greater than 25% from baseline. The study was 
approved by the Royal North Shore Hospital Ethics Committee (protocol number 
1101-003A). The Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes was followed in this study. Animals were anaesthetised using 
short inhalational anaesthesia with 2 % isoflurane for minor procedures. Animals 
were euthanised under 2% isoflurane anaesthesia using cardiac puncture terminally.  
 
4.2.2 Experimental design  
 
The SGLT2i empagliflozin (provided by Boehringer-Ingelheim Germany) was 
administered by daily oral gavage (Instech Lab, USA) using 1% 
hydroxyethylcellulose (Sigma Aldrich) as a vehicle. Current best practice is renin-
angiotensin-aldosterone blockade. Hence telmisartan (Boehringer-Ingelheim, 
Germany) at a dose of 3mg/kg /day was administered in drinking water as a 
comparative limb. Empagliflozin and telmisartan were initiated at 13 weeks of age. 
Mice were killed at 32 weeks of age. The groups were as below. 
1. Control (ctrl, n=12) 
2. Control receiving empagliflozin 10mg/kg daily (ctrl+empa, n=8) 
3. Diabetic (dm, n=12) 
4. Diabetic receiving empagliflozin 10mg/kg daily (dm+empa, n=10) 
5. Diabetic receiving telmisartan, 3 mg/kg in drinking water (dm+tel=7) 
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4.2.3 Measurement of physiological parameters  
 
Body weight was assessed monthly. Blood pressure was measured using a 
noninvasive tail vein cuff method (CODA BP apparatus, Kent Scientific, USA) 
preterminally (Table 1).  
 
4.2.4 Urine biochemistry  
 
Urine was collected at three different time points (48 hour post initiation of 
treatment, 4-6 weeks after initiation of treatment using metabolic cages and 
terminally using bladder puncture). Urine creatinine was measured using a picric 
acid method (Creatinine Companion, Exocell Inc., USA). Urinary glucose was 
measured using Abbot Architect C16000 analyser. Urine albumin was measured 
using Elisa (Albuwel, Exocell Inc., USA). 
 
4.2.5 Kidney tissue harvest  
 
The unperfused left kidney was harvested and snap frozen after embedding in OCT 
compound. The right kidney was perfused with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde (PFA) and subsequently fixed in 10% neutral 
buffered formalin for 24-48 hours.  
 
 
 
 
	 56 
4.2.6 Histology  
 
Formalin fixed paraffin embedded (FFPE) kidney sections were stained with 
Masson’s Trichrome, Sirius Red and Periodic Acid Schiff.  Assessment of 
histological change was done in a blinded manner. The Glomerulosclerotic index 
(GSI) was calculated based on previously described methodology[124].  Atrophic 
tubules were defined by dilatation, epithelial shedding and thinning of epithelium. 
Tubular damage was scored by counting the number of atrophic tubules per 400 
tubules at X 200 magnification.  
    
Immunohistochemistry for fibronectin and TLR2 were done on 4 micron paraffin 
embedded sections using rabbit anti mouse fibronectin (F3468, Sigma Aldrich, 
USA) at a concentration of 1:2000 and rabbit anti mouse TLR2 (Imgenex, San 
Diego, California) at a concentration of 1:250. The chromogenic reaction was 
carried out with 3,3′-diaminobenzidine chromogen (Dako, Australia) solution for 
10 minutes. Immunohistochemistry for F4/80 staining was done on 10 micron 
frozen section slides. They were incubated with rat anti mouse F4/80 (MCA497R, 
ABD Serotec, USA) at a concentration of 1:100 for one hour followed by HRP 
tagged goat anti Rat antibody at a concentration of 1:200 (ABD Serotec, USA).  
     
F4/80 positive cells per high power field were counted and averaged for each slide. 
The degree of interstitial collagen content in Masson’s and Sirius red stains was 
assessed in a blinded manner using Image J by identifying the percentage of 
interstitial collagen positive region at X 200 magnification in 5 randomly selected 
regions. Glomerular fibronectin was quantified using Image J at X 400 
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magnification after selecting 10-15 glomeruli at random and quantifying the 
percentage of fibronectin positive area in each glomerulus. Appropriate negative 
and positive controls were used for all immunohistochemistry stains.  
 
4.2.7 Real time PCR experiments  
 
Total RNA was extracted from kidney tissue using Trizol. cDNA was synthesised 
using Superscript III (Life Technologies) first strand synthesis. The cDNA was 
subjected to standard curve measurement to ensure efficiency prior to real time 
PCR, which was done using SYBR green (Life Technologies, Australia) for MCP-
1, fibronectin, TGFβ, collagen IV, GLUT1 and GLUT2 using actin as the 
endogenous control. PCR for SGLT2 and SGLT1 were done using Taqman PCR 
Universal Mastermix (Applied Biosystems). The RTPCR was performed on the 
AB7900 machine (Applied Biosystems, Australia). Gene expression was quantified 
relative to actin. The primers are listed in Table 2. 
 
4.2.8 Western blot  
 
Frozen tissue was homogenized with Quiagen Tissue Ruptur in 1.5 ml of cold 
20mM HEPES buffer, pH 7.2, containing 1mM EGTA, 210mM mannitol, 70mM 
sucrose and centrifuged at 1.500 x g for 5 min at 4°C. Samples were then analysed 
by SDS gel electrophoresis (Novex, Life technologies, Australia) and electroblotted 
to Hybond Nitrocellulose membranes (Amersham Pharmacia Biotech, Bucks, UK). 
Membranes were then probed with primary antibodies to GLUT1 (ab652, Abcam, 
Cambridge, UK), SGLT2 (sc98975, Santa Cruz, USA) and actin (Santa Cruz, 
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USA). Proteins were visualized using Luminata Western HRP Substrate (Millipore) 
in a LAS 4000 image reader (GE Healthcare Life Sciences). Analysis was 
performed using Image J software (NIH, USA).  
 
4.2.9 Statistical analysis  
 
Statistical analysis was done using Graph Prism. Data are expressed as mean ± 
standard error of mean. A P value < 0.05 was considered statistically significant. 
Significance was assessed using paired t- test for analysing the difference in insulin 
requirement of diabetic mice before and after initiation of empagliflozin. Blood 
glucose profile during the study was measured using repeated measures ANOVA. 
ANOVA with Bonferroni’s correction for multiple comparisons was used for all 
other statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
	 59 
4.3 Results 
 
4.3.1 Diabetic mice had similar fasting glucose levels  
 
The blood glucose levels were measured monthly, starting two weeks after 
induction of diabetes and average values were calculated over the duration of the 
experiment for all groups. The diabetic mice displayed significantly elevated blood 
glucose levels at 21.4 mmol/L after induction with streptozotocin (Table 4.1) 
maintained with long acting insulin and empagliflozin treatments, while the glucose 
level was matched in all the diabetic limbs throughout the experiment (Figure 4.1A) 
as planned.  
 
4.3.2 Empagliflozin induced glycosuria in non diabetic mice  
 
The control + empagliflozin group displayed nearly 200 fold increase in urinary 
glucose levels compared to the control mice (Table 4.1). The urinary glucose 
excretion among all diabetic mice was significantly higher than control mice (Table 
4.1).  
 
4.3.3 Empagliflozin reduced insulin requirement and accentuated poor weight 
gain in diabetic mice  
 
Comparisons were made between the thrice weekly insulin dose of diabetic mice in 
the diabetic + empagliflozin group, before and after initiation of empagliflozin. The 
insulin requirements of the diabetic mice were significantly reduced after initiation 
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of empagliflozin (Figure 4.1B). All diabetic mice had poor weight gain which was 
pronounced in the diabetic + empagliflozin group (Table 4.1).  
 
4.3.4 Telmisartan but not empagliflozin reduced terminal urinary albumin 
excretion in diabetic mice  
 
The terminal urinary albumin to creatinine ratio was elevated in the diabetic mice.  
Treatment with empagliflozin did not improve albuminuria in diabetic mice. This 
was significantly reduced by treatment with telmisartan in diabetic mice. In the 
early stages of the illness, SGLT2 inhibition shows a non significant trend towards 
improving albuminuria in diabetic mice, which is not maintained as the disease 
progresses (Table 4.1).  
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Table 4.1 Physical and clinical parameters  
 
 
Control 
(n=12) 
Control 
+empagliflo
zin 
(n=8) 
Diabetic 
(n=12) 
Diabetic 
+empagliflo
zin 
(n=10) 
Diabetic 
+telmisartan 
(n=7) 
Gain in 
weight 
(gram) 
5.4 ± 0.5 3.9 ± 1.0 2.4 ± 0.7** 0.8 ± 0.6** 3.1 ± 0.6* 
Left 
kidney/ body 
weight ratio 
(%) 
0.77 ± 
0.04 0.80 ± 0.03 0.91 ± 0.06 0.82 ± 0.08 0.89 ± 0.08 
Average 
blood sugar 
(mmol/L) 
11.0 ± 0.3 11.5 ± 0.4 21.1 ± 0.4** 
22.1 ± 
0.6** 
22.9 ± 
0.7** 
Systolic BP  
(mm Hg) 120 ± 2 128 ± 4 117 ± 2 122 ± 6 118 ± 10 
24 hour 
urine 
glucose 
excretion 
(µmol/day) 
2.6 ± 0.3 456.5 ± 74.4 
3038.0 ± 
864.8* 
3551.0 ± 
35.9** 
3462.0 ± 
320.4** 
Mid 
experimental 
albumin/crea
tinine ratio 
(µg/mg) 
133 ± 25 197 ± 48 987 ± 336* 463 ± 136 180 ± 121 
Terminal 
albumin/crea
tinine ratio 
(µg/mg) 
224 ± 36 290 ± 56 1474 ± 388* 
1697 ± 
596* 80 ± 30
# 
 
Data are mean ± standard error of mean.  
*=P<0.05 vs control group 
**=P<0.001 vs control group 
#=P<0.05 vs diabetic group. 
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Figure 4.1. Blood glucose levels among diabetic mice were matched throughout the 
study and showed similar glucose levels among the diabetic mice at 1, 2, 3, 4 and 5 
months post diabetes induction and were significantly higher than control mice (A). 
Empagliflozin reduced insulin requirement in diabetic mice (B). The comparison 
was made between average insulin requirement per dose administered thrice weekly, 
before and after initiation of empagliflozin. Data are expressed as mean ± SEM with 
*=P<0.05 and **=P<0.001 vs ctrl. 
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4.3.5 Telmisartan but not empagliflozin reduced the degree of 
glomerulosclerosis and glomerular fibronectin deposition in diabetic mice  
 
The untreated diabetic mice (Figure 4.2C) developed significant glomerulosclerosis 
in comparison with control mice (Figure 4.2A) Treatment with empagliflozin 
showed no improvement in the glomerulosclerotic index in diabetic mice (Figure 
4.2D), whereas diabetics treated with telmisartan (Figure 4.2E) had significantly 
lower glomerulosclerotic scores. The diabetic mice (Figure 4.2I) developed 
significant glomerular fibronectin deposition in comparison with control mice 
(Figure 4.2G). There was no improvement with concurrent empagliflozin therapy 
(Figure 4.2J), while telmisartan was associated with a significant reduction in 
glomerular fibronectin deposition in diabetic mice (Figure 4.2K). 
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Figure 4.2 (A-F) 
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Figure 4.2 (G-L) 
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Figure 4.2. Diabetic mice demonstrated increased glomerulosclerosis and 
glomerular fibronectin deposition, which was improved by telmisartan but not by 
empagliflozin. Representative photographs of PAS stained sections for A) ctrl, B) 
ctrl + empa, C) dm, D) dm + empa and E) dm + tel groups and quantification of 
glomerulosclerosis by glomerulosclerotic index (F). Representative photographs of 
immunohistochemistry for glomerular fibronectin in G) ctrl, H) ctrl + empa, I) dm, 
J) dm + empa and K) dm + tel groups and quantification of glomerular fibronectin 
by Image J (L) (Magnification=original X400). Data are expressed as mean ± SEM 
with **=P<0.001 vs ctrl,  #=P<0.05 vs dm and ##=P<0.001 vs dm. 
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4.3.6 Empagliflozin did not reduce tubulointerstitial inflammation in diabetic 
mice  
 
The diabetic mice (Figure 4.3C) developed significantly increased tubulointerstitial 
infiltration of activated macrophages, demonstrated by F4/80 staining, compared to 
controls (Figure 4.3A). Concurrent treatment with empagliflozin did not improve 
this in diabetic mice (Figure 4.3D). However, telmisartan therapy significantly 
reduced macrophage infiltration in diabetic  (Figure 4.3E). The diabetic mice also 
displayed increased tubular expression of TLR2 (Figure 4.3I). Empagliflozin did 
not modify the upregulation of TLR2 while telmisartan treated diabetic mice 
showed TLR2 expression not significantly different to that in control mice (Figure 
4.3J and 4.3K).  
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Figure 4.3 (A-F) 
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Figure 4.3 (G-L) 
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Figure 4.3. Diabetic animals demonstrated increased tubulointerstitial inflammation, 
which was not ameliorated by empagliflozin.  Representative photographs of 
immunohistochemistry for tubulointerstitial F4/80 stain for activated macrophages in 
A) ctrl, B) ctrl + empa, C) dm, D) dm + empa, E) dm + tel groups (Magnification 
=original X 400) and quantification of F4/80 positive cells in tubulointerstitium (F) 
which was done by calculating the average number of F4/80 positive cells per high 
power field (HPF) in each group.  Representative photographs of 
immunohistochemistry for tubular TLR2 in G) ctrl, H) ctrl + empa, I) dm, J) dm + 
empa, K) dm + tel groups (Magnification =original X 200) and quantification of 
tubular TLR2 expression by Image J (L).  (Data are expressed as mean ± SEM with 
*=P<0.05 vs ctrl, **=P<0.001 vs ctrl and #=P<0.05 vs dm).  
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4.3.7 Telmisartan but not empagliflozin reduced the degree of tubular atrophy 
and tubulointerstitial fibrosis in diabetic mice  
 
The diabetic mice (Figure 4.4C) developed significant tubular atrophy in comparison 
with control mice (Figure 4.4A). Empagliflozin did not reduce tubular atrophy 
(Figure 4.4D), while temisartan treated diabetic mice showed tubular atrophy not 
significantly different to control mice (Figure 4.4E). The degree of interstitial 
fibrosis was assessed by Sirius Red sensitive collagen staining (Figures 4.4G-K) and 
Masson’s staining (Figures 4.4M-Q). The diabetic mice showed a non significant 
trend towards increased collagen deposition with the sirius red stain. However with 
the Masson’s stain, the diabetic mice had significantly increased collagen deposition 
(Figure 4.4O), which was not improved by empagliflozin (Figure 4.4P). Telmisartan 
treated diabetic mice showed tubulointerstitial fibrosis not significantly different to 
that of control mice (Figure 4.4Q). 
 
 
 
 
 
 
 
 
 
 
	 74 
Figure 4.4 (A-F) 
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Figure 4.4 (G-L) 
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Figure 4.4 (M-R) 
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Figure 4.4. Diabetic mice demonstrated tubular atrophy and tubulointerstitial 
fibrosis, which was not improved by empagliflozin and partially reduced by 
telmisartan.  Representative photographs of PAS stained sections of 
tubulointerstitium in A) ctrl, B) ctrl + empa, C) dm, D) dm + empa, E) dm + tel 
groups and F) Quantification of tubular atrophy in all groups was done by counting 
the number of atrophic tubules per 400 tubule count (Data are expressed as mean ± 
SEM with *=P<0.05 vs ctrl). Representative photographs of tubulointerstitial 
picrosirius red stain in G) ctrl, H) ctrl + empa, I) dm, J) dm + empa, K) dm + tel 
groups and L) Quantification of tubulointerstitial Sirius red positive collagen content 
by Image J.  Representative photographs of Masson’s stain in M) ctrl, N) ctrl + 
empa, O) dm, P) dm + empa, Q) dm + tel groups and R) Quantification of Masson’s 
positive collagen content by Image J (Magnification =original X 200). (Data are 
expressed as mean ± SEM with *=P<0.05 vs ctrl, **=P<0.001 vs ctrl).  
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4.3.8 Empagliflozin did not improve the renal cortical transcription of 
inflammatory or profibrotic cytokines in diabetic mice  
 
To determine whether empagliflozin or telmisartan modulated the cortical 
transcription of MCP-1, collagen IV, fibronectin and TGFβ in diabetes, we 
performed real time PCR from RNA derived from renal cortical tissue. The 
transcription of MCP-1, fibronectin and TGFβ was increased in diabetic mice and 
was unchanged by empagliflozin (Figure 4.5). Diabetic mice treated with 
telmisartan displayed MCP-1 (Figure 4.5A) and fibronectin (Figure 4.5D) 
transcription, which was not significantly different to control mice although TGFβ 
transcription was noted to be increased in this group (Figure 4.5C). No change was 
noted in the transcription of collagen IV between control and diabetic mice (Figure 
4.5B) 
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Figure 4.5 
 
Figure 4.5. Diabetic mice showed increased renal cortical transcription of 
inflammatory and fibrotic cytokines, which was not improved by empagliflozin. 
Real time PCR results for renal cortical transcription of A) MCP-1, B) Collagen 4, 
C) TGFβ and D) Fibronectin relative to actin (Data are expressed as mean ± SEM 
with *=P<0.05 vs ctrl and **=P<0.001 vs ctrl). 
 
 
 
	 80 
4.3.9 Empagliflozin significantly increased GLUT1 transcription in diabetic 
mice although no difference was noted in GLUT1 protein expression  
 
There was no difference in mRNA transcription of any glucose transporters 
between diabetic and non diabetic mice (Figure 4.6). Empagliflozin treated diabetic 
mice showed a significant increase in GLUT1 transcription compared to other 
diabetic mice (Figure 4.6A) and telmisartan treated diabetic mice showed increased 
SGLT2 transcription compared to diabetic mice (Figure 4.6D). However there was 
no difference in either SGLT2 or GLUT1 protein expression among the different 
groups (Figure 4.6E-H).  
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Figure 4.6 
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Figure 4.6. Empagliflozin increased renal GLUT1 transcription in comparison with 
untreated diabetic mice although renal protein expression of GLUT1 and SGLT2 
were unchanged. Real time PCR results for A) GLUT1, B) GLUT2, C) SGLT1 and 
D) SGLT2 expressed relative to actin. Expression levels of renal GLUT1 protein (E 
and F) and SGLT2 (G and H) relative to actin (Data are expressed as mean ± SEM 
with  #=P<0.05 vs dm) 
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Table 4.2. PCR primer sequences 
Target Forward Reverse Source 
MCP-1 GCCTGCTGTTCACAGTTGC CAGGTGAGTGGGGCGTTA Sigma 
Collagen IV TTAAAGGACTCCAGGGACCAC CCCACTGAGCCTGTCACAC Sigma 
Fibronectin CACGGAGGCCACCATTACT CTTCAGGGCAATGACGTAGAT Sigma 
TGFβ TCAGACATTCGGGAAGCAGT ACGCCAGGAATTGTTGCTAT Sigma 
Actin AAGGCCAAGCGTGAAAAGAT GTGGTAGGACCAGAGGCATAC Sigma 
GLUT1 AACATGGAACCACCGCTACG GTGGTGAGTGTGGTGGATGG Sigma 
GLUT2 ATCGCCCTCTGCTTCCAGTAC GAACACGTAAGGCCCAAGGA Sigma 
SGLT1 Mm00451203_m1                                                                                            (Applied Biosystems) 
SGLT2 Mm00453831_m1                                                                                            (Applied Biosystems)  
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4.4 Discussion 
 
To our knowledge this is the first study to evaluate the renoprotective effects of 
SGLT2 inhibition independent of glucose lowering. We used a type 1 diabetic 
eNOS knockout mouse model, validated by the Animal Models of Diabetic 
Complications Consortium (AMDCC) [123], with matched glycaemia across 
experimental groups. Although we have previously demonstrated that 
empagliflozin reduced high glucose induced expression of inflammatory and 
fibrotic markers in in vitro studies of human kidney PTC, our results show that it 
did not confer renoprotection in this in vivo model. This was in contrast to the 
renoprotection afforded by the angiotensin receptor blocker (ARB) telmisartan. 
    
The strength of our study is based on the determination of renal parameters in a 
setting of matched high blood glucose levels among diabetic groups. In our study, 
empagliflozin caused a 200 fold increase in glycosuria in control mice compared to 
control mice not receiving the drug, which confirms that empagliflozin was 
absorbed and achieved sufficient concentration in the lumen to actively inhibit PTC 
SGLT2. Furthermore the diabetic mice receiving empagliflozin had less insulin 
requirements and less weight gain reflecting the efficacy of empagliflozin in 
inducing glycosuria in our model. As the effectiveness of SGLT2 inhibition is 
dependent on the creatinine clearance with decreased efficiency as creatinine 
clearance decreases we would expect the efficacy to decrease as the severity of 
diabetic nephropathy increases [125].  
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In contrast to our findings, there are recent animal studies wherein SGLT2i have 
shown significant renal benefit [126, 127]. There are however important differences 
in these studies from our current study. In the study by Nagata et al, a type 2 
diabetic model was used and diabetic mice treated with the SGLT2i tofogliflozin 
had lower plasma glucose levels, making interpretation of renal benefit independent 
of glucose lowering difficult. The second study by Kojima et al utilized older (> I 
year old) type 2 diabetic rats with established diabetic nephropathy and showed that 
although matched for glucose levels the diabetic mice receiving the SGLT2i 
luseogliflozin had better renal outcomes than the mice receiving insulin. The mice 
receiving insulin had 10 fold higher plasma insulin levels. Studies have shown that 
insulin itself can increase TGFβ-1 gene expression by mesangial cells [128] and 
can promote glomerular and interstitial fibrosis [129]. Furthermore, in a recent 
publication, Wright et al has described the probable role of insulin as an agonist in 
stimulating SGLT2 activity through activation of protein kinase A and C [130]. 
This would explain an increase in glucose reabsorption in type 2 diabetic mice with 
high insulin levels and provide an explanation for better outcomes with SGLT2 
inhibition in this model.  Current data available from the registration trials of 
SGLT2i is limited, but suggests a stable reduction in estimated GFR than reverts to 
baseline after cessation of the drug. This occurs in association with a reduction in 
albuminuria. However, renoprotective benefits cannot be concluded from available 
clinical data. 
     
Our studies are consistent with two recent studies by Vallon et al. The first study 
used SGLT2 knockout mice showing that although there was an improvement in 
glucose control and glomerular hyperfiltration, there was no improvement in kidney 
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growth or injury [72]. An important difference between our own study and this 
study is that there was an improvement in blood glucose among mice treated with 
empagliflozin. Moreover it was noted that after 18 weeks of diabetes, no increase in 
TGFβ expression was observed in the renal cortex by their group. Conversely, we 
did demonstrate increased transcription of TGFβ in the renal cortex of diabetic 
animals although there was no statistically significant improvement with 
empagliflozin. Similar to Vallon’s study, we found a statistically non significant 
trend towards decreased SGLT2 protein expression in diabetic mice, which may 
have contributed to reduced renoprotection by empagliflozin. However this cannot 
explain the significant diabetic changes in empagliflozin treated mice in contrast to 
improvement in the telmisartan group. The second study by Vallon et al in Akita 
mice, a type 1 model of diabetes, demonstrated that empagliflozin was effective in 
reducing GFR independent of blood glucose but the reduction in albuminuria, 
kidney growth and inflammation was thought to be the result of concomitant 
glucose lowering [131]. Our study in contrast was designed to evaluate renal 
outcome independent of glucose levels, which has been a confounding variable in 
all studies to date.  
     
There are several possible reasons for our findings. Firstly, as the blood glucose 
levels were similarly elevated among all diabetic mice, this has resulted in 
glomerular injury, as SGLT2 inhibition does not prevent glucose entry into the 
glomerular compartment. It is known that progressive glomerular injury can cause 
tubulointerstitial damage through a number of different mechanisms including 
misdirected filtration (filtrate leakage external to the tubular lumen), obstructed 
filtration and proteinuria as a result of damage to the glomerular filtration barrier 
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[132]. This then initiates a cycle of progressive tubulointerstitial injury, which is 
not prevented by blocking glucose entry into the PTC. Secondly, the lack of 
renoprotection seen in our study could be the result of incomplete inhibition of 
glucose reabsorption by empagliflozin. We know that SGLT2 inhibition only 
prevents reabsorption of 40% of glucose and this could be due to multiple reasons 
[133]. GLUT1 is a major glucose transporter in mesangial cells and is a facilitative 
transporter of glucose in the S3 segment of the basolateral aspect of the tubular cell 
with bidirectional transport properties [134]. It is possible that hyperglycaemia 
could influence the movement of glucose into the tubular cell from the basolateral 
aspect and is not modified by empagliflozin. This is not dependent on an increase in 
GLUT1 protein expression. 
      
The diabetic mice in our model had matched high glucose levels, which is not 
reflective of the well controlled diabetic patient. However this was necessary in the 
design of the experiment to test the hypothesis whether SGLT2 inhibition can offer 
renoprotection independent of glucose lowering. There is evidence to suggest that 
SGLT2i can reduce diabetic nephropathy when glycaemic control is optimal in a 
Type 2 diabetic animal model and is even more pronounced when used in 
combination with an angiotensin receptor blocker [127]. However this could have 
been due to glucose lowering rather than specific SGLT2 inhibition. In summary, 
we have shown that although empagliflozin reduces high glucose induced 
inflammatory and fibrotic markers in vitro; it does not have renoprotective benefits 
independent of glucose lowering in vivo. 
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Chapter 5: Dipeptidyl peptidase-4 inhibitors and diabetic 
nephropathy 
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5.1 Dipeptidyl peptidase-4  
 
Dipeptidyl peptidase-4 (DPP4), which is also known as CD26, is a member of the 
serine peptidase/prolyl oligopeptidase gene family that includes the membrane-bound 
peptidases, fibroblast activation protein (FAP)/separase; the resident cytoplasmic 
enzymes, DPP8 and DPP9; and the nonenzymatic members, DPP6 and DPP10, which 
are present in neuronal membranes, and prolyl endopeptidase [135]. DPP4 is a unique 
protein found in many organ systems and has many functions. It was first identified as 
an enzyme present in liver and kidneys with the ability to hydrolyse glycine-proline 
dipeptide from a synthetic substrate glycyl-prolyl-β naphthalamide [136]. DPP4 is 
one of the membrane bound proteases specific for proline and less commonly alanine 
as the penultimate amino acid and cleaves the terminal dipeptide. This enzyme has an 
endless list of possible substrates although short peptides are considered as effective 
substrates rather than larger cytokines, which have not been shown to be cleaved by 
DPP4 [137]. DPP4/CD26 has a central cavity, which contains the hydrolase and 
propeller domains of the proteases. Hence this prevents large peptides from becoming 
substrates for proteolysis [137]. Moreover, DPP4 also demonstrates substrate specific 
catalysis where replacement of single amino acid can increase or decrease the 
efficiency of hydrolysis [137]. The most important substrates for DPP4 are glucagon 
like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) as they are involved 
in post meal glycaemic control. Cleavage of intact GLP-1 and GIP by DPP4 results in 
reduced affinity of cleaved product with its receptor and reduces the glucose 
regulation potential of the cleaved product [135]. DPP4 has also been shown to act as 
a receptor whereby engagement by anti CD26 antibodies in human hepatocarcinoma 
derived-PLC/PRF/5 cells results in tyrosine phosphorylation of several proteins in the 
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intracellular domain [138]. DPP4 also has a significant co- stimulatory role in T cells 
and interacts with both CD45 and adenosine deaminase (ADA) through its extra 
cellular domain and participates in signal transduction [139]. DPP4 has been shown to 
bind to collagen and fibronectin and also participates in apoptosis [137]. In addition, 
DPP4 exhibits significant protein interaction with other membrane bound proteins, 
namely cation independent mannose-6-phosphate receptor (CIM6PR) and this 
interaction has been demonstrated to participate in T cell activation [140]. This 
interaction has recently been suggested as playing a possible role in activation of 
TGFß [8]. It has also been shown that DPP4 interacts with integrin ß1, which also 
plays a role in TGFß activation and diabetic nephropathy [141]. These interactions 
play a significant role in the pathogenesis of diabetic nephropathy independent of the 
glycaemic effects of DPP4.  
 
DPP4 exists in two forms, a membrane bound form and soluble form. The membrane 
bound form has residues 1-766 and the soluble form has residues 39-766 as it does not 
contain the trans-membrane and intracellular domains [135]. It is noted to be mostly 
present as a dimer where its enzymatic activity is maximal [135]. It has been shown 
that the soluble from is secreted from the membrane bound DPP4 [142]. 
 
5.2 The incretin system  
 
The incretin hormones are released by the gut in response to a meal and may be 
responsible for up to 70% of postprandial insulin secretion. They include glucagon 
like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) [143]. 
Apart from insulin secretion, the incretin hormones perform a number of functions 
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designed to improve glycaemic control. This includes suppression of glucagon 
secretion, increase in pancreatic ß cell mass and increased differentiation of islet 
precursor cells into ß cells, inhibition of ß cell apoptosis, deceleration of gastric 
emptying to promote slow glucose release, suppression of satiety and weight loss 
[144]. GLP-1 and GIP have a biphasic secretion and their activity is terminated by 
DPP4. GLP-1 has a half life of < 2 minutes and GIP has a half life of 5-7 minutes 
[145]. Meal induced secretion of GLP-1 is diminished in patients with type 2 diabetes 
and this contributes to poor glycaemic control in these patients [146].  
    
This has led to the development of incretin based therapy for diabetes whereby use of 
parenteral long acting GLP-1 analogues and oral DPP4 inhibitors (DPP4i) are used to 
improve diabetic control (Figure 5.1). The two classes of incretin based therapies 
include GLP-1 receptor agonists and DPP4i. The GLP-1 agonists includes liraglutide, 
a long acting agent with a half life of 11-13 hours and short acting agent, namely 
exenatide which has a half life of 2.4 hours [147]. There are several DPP4i in clinical 
practice. These drugs are divided into peptidomimetics or non-peptidomimetics 
according to their chemical structure, based on whether they mimic the DPP4 
substrate. These drugs have different pharmacodynamic properties with linagliptin 
having the highest potency. They also display selectivity for DPP4 compared to other 
members of this family with selectivity ranging from  <100 fold for vildagliptin and 
saxagliptin to >14000 fold for alogliptin [148].  
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5.3 Pathogenesis of diabetic nephropathy  
 
Diabetic nephropathy is the commonest cause of chronic kidney disease worldwide. 
The incidence of diabetic nephropathy has been increasing in the developed world 
although the prevalence as a percentage of diabetic patients is stable [62]. However 
the incidence and prevalence of diabetes and diabetic nephropathy is predicted to 
increase in the developing world [149]. This has an impact on national resources and 
is a huge public health problem. There have been no significant treatment measures to 
prevent the progression of diabetic nephropathy since the advent of medications 
blocking the renin angiotensin aldosterone system (RAAS) and hence there remains a 
large treatment gap.  
 
The pathogenesis of diabetic nephropathy is complex. A very simplistic view of 
diabetic nephropathy involves hemodynamic and metabolic abnormalities associated 
with diabetes mellitus. It has been shown that glomerular hyperfiltration occurs early 
in diabetes and in fact even in prediabetes in proportion with the degree of 
hyperglycaemia [150]. However the classical concept of hyperfiltration, albuminuria 
and subsequent loss of glomerular filtration is now not classically observed in patients 
with Type 2 diabetes mellitus [151]. It has also been shown that mesangial stretch 
results in GLUT-1 overexpression and increased TGFß production [152]. Mesangial 
stretch also results in vascular permeability factor (VPF) or vascular endothelial 
growth factor (VEGF) production, which may contribute to proteinuria [153].  
 
However the underpinning factor in diabetic complications is the constant exposure to 
high glucose demonstrated in many studies including the UKPDS and DCCT 
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(Diabetes Control Complications Trial) [154, 155]. The Banting lecture by Brownlee 
in 2004 integrated the various components involved in the pathobiology of diabetes. 
These pathogenic processes predominate in cells, which cannot regulate intracellular 
glucose entry in the setting of hyperglycaemia. During hyperglycaemia, there is 
increased flux of glucose through the polyol pathway, which reduces intracellular 
reduced glutathione resulting in increased susceptibility to oxidative stress. There is 
increased production of advanced glycation end products, which regulates gene 
transcription. There is increased activation of protein kinase C resulting in gene 
transcription, which increases profibrotic cytokines, namely (TGFß and 
vasoconstrictor agents, namely endothelin-1. Increased glucose flux through 
hexosaminase pathway again increases transcription of TGFß and plasminogen 
activator-1, another profibrotic cytokine [156].  
 
The net result of hyperglycaemia is the perturbation of various physiological 
processes and activation of pathological processes culminating in glomerular and 
tubulointerstitial fibrosis. Glomerulosclerosis is related to increased expression of the 
GLUT-1 transporter in the mesangial cells, leading to activation of all the 
pathological pathways mentioned previously. In addition there is reduction in 
endothelial nitric oxide synthase, bradykinin 2 receptor blockade, plasminogen 
activator inhibitor-1 (PAI-1) activation, micro RNA regulation of TGFß signaling and 
activation of JAK-STAT pathway through angiotensin II activation which collectively 
contribute to diabetic glomerulosclerosis [157]. The proximal tubular cell (PTC) is a 
very important site and plays an active role in pathogenesis of tubulointerstitial 
fibrosis in the diabetic kidney. It is the site for reabsorption of almost all of the 
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filtered glucose and a component of the filtered sodium through sodium glucose 
cotransport systems. 
 
Diabetes induces early hyperplasia of the proximal tubules and various growth factors 
have been implicated including but not limited to insulin like growth factor-1 (IGF-1), 
platelet derived growth factor (PDGF), fibroblast growth factor (FGF) and VEGF. 
These changes induce increased ornithine decarboxylase activity leading to PTC 
hyperplasia. These growth factors also stimulate protein kinase C activity, which 
further stimulates cellular proliferation. These processes in addition to proteinuria 
activate inflammation, which contributes to and culminates in tubulointerstitial 
fibrosis. In addition, proximal tubular hypertrophy and hyperplasia stimulates further 
glucose and sodium reabsorption thereby exacerbating hyperglycaemia and 
potentiating hyperfiltration through inhibition of tubuloglomerular feedback [158]. 
 
The RAAS plays an important role in diabetic nephropathy. Hyperglycaemia 
stimulates increased production of renin and activates RAAS, which increases 
reactive oxygen species and promotes inflammatory and fibrotic cytokines eventually 
promoting glomerulosclerosis and tubulointerstitial fibrosis. These pathogenic 
processes culminate in microvascular complication of diabetes including diabetic 
nephropathy. TGFß is a central profibrotic cytokine in the pathogenesis of diabetic 
nephropathy. It increases PAI-1 synthesis, fibronectin production and connective 
tissue growth factor (CTGF), which promote extracellular deposition of collagen. 
TGFß induces fibrosis mainly through the Smad pathway, especially the downstream 
signaling molecules Smad2 and Smad3. Eventually this results in increased mesangial 
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expansion, glomerular basement membrane thickening, glomerulosclerosis and 
tubulointerstitial fibrosis with loss of function [159]. 
 
Inflammation plays a significant role in diabetic nephropathy and the role of various 
aspects of the immune system in the development of diabetic nephropathy is 
becoming more apparent. Formation of reactive oxygen species (ROS) is a prominent 
feature of early diabetic nephropathy. It has been shown that endothelial nitric oxide 
synthase (eNOS) is upregulated in diabetic nephropathy. However in diabetes, there is 
reduced production of nitric oxide (NO) and increased production of ROS due to 
uncoupling of eNOS [160] The lack of NO results in loss of vasodilation, reduced 
ability to inhibit platelet aggregation and reduced ability to suppress inflammation 
[161]. It has been shown that macrophage infiltration increases in diabetes and the 
degree of glomerulosclerosis and tubulointerstitial fibrosis correlates with the degree 
of infiltration [162]. In addition, a number of inflammatory cytokines are activated in 
diabetes and form part of a number of pathways including but not limited to Janus 
Kinase (JAK), signal transducer and activator of transcription (STAT), tyrosine 
kinase (TyK), myeloid differentiation factor-88 (Myd-88) and NF-κB inducing kinase 
(NIK) [163]. The profibrotic and proinflammatory cytokines result in activation of 
resident fibroblasts resulting in transformation into myofibroblasts, which produce a 
large amount of extracellular matrix [164]. 
 
Innate immunity has been shown to play a significant role in diabetic nephropathy. 
There is increasing evidence that high glucose triggers the increased expression of 
Toll like receptors 4 (TLR4) in tubular epithelial cells with downstream inflammatory 
signaling, namely NF-κB which in turn activates inflammatory cytokines IL-6 and 
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CCL-2 and is associated with increased macrophage infiltration [115]. Similarly, it 
has been shown that high glucose induces Toll like receptor 2 (TLR2) expression in 
proximal tubular cells and increases NF-κB activation through High Molecular Group 
Box-1 (HMGB-1) resulting in downstream activation of inflammatory and 
chemotactic cytokines [116]. The innate immune system is activated to produce 
interleukin 8 (IL-8) through a series of germ line coded pattern recognition receptors 
(PRRs). One of these PRRs is the nucleotide binding oligomerisation domain like 
receptors (NLRs). Cytosolic NLRs associate with apoptosis associated speck like 
protein and procaspace-1 to form a large multiprotein complex called the 
inflammasome, which leads to autocatalytic activation of caspace-1 [165]. It has 
recently been shown that Nlrp3 expression is increased in diabetic mice even before 
albuminuria and glomerular mesangial matrix expansion. It was also shown that 
Nlrp3 deficient mice were protected from albuminuria and mesangial expansion 
despite high glucose levels, suggesting a strong role for the inflammasome in diabetic 
nephropathy [166].  
 
The incretin system has a role in modulation of pathogenesis of diabetic nephropathy. 
GLP-1 agonists and DPP4i have been shown to improve inflammation and fibrosis in 
vitro and in animal models of diabetes and hold promise for additional renoprotective 
benefits.  
 
5.4 Role of GLP-1 in diabetic nephropathy 
 
In addition to blood pressure lowering and RAAS blockade, the most important 
strategy in preventing onset and progression of diabetic nephropathy is excellent 
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control of blood glucose. DPP4i help prolong the action of GLP-1 resulting in better 
glycaemic control postprandially. However GLP-1 has been shown to have benefits 
beyond glucose lowering in preventing micro and macrovascular complications of 
diabetes, through both GLP-1 receptor dependent and independent effects. 
 
5.4.1 Evidence from in vitro studies and animal studies 
 
It has been shown recently that loss of GLP-1 receptor in C57BL6/Akita mice results 
in upregulation of NOX-4 expression and increased oxidative stress levels. This 
results in progressive diabetic nephropathy in this mouse model, which is otherwise 
resistant to diabetic nephropathy. It was also noted that loss of the GLP-1 receptor 
increased renal expression of connective tissue growth factor (CTGF) and TGFß1 in 
addition to Thrombospondin-1, which is an endogenous activator of TGFß1. It is 
proposed that GLP-1 acts via increased intracellular cyclic adenosine mono phosphate 
(CAMP) and protein kinase A (PKA) to inhibit NADPH oxidase. It has been shown 
that the GLP-1 analogue exendin-4 inhibited the proliferation of mesangial cells and 
glucose induced upregulation of TGFß1 and CTGF expression [167]. Liraglutide, a 
long acting GLP-1 analogue was noted to suppress the progression of diabetic 
nephropathy in KK/Ta-Akita mice without major differences in insulin levels, glucose 
tolerance and metabolic parameters [168]. It has been shown recently by Mima et al 
that GLP-1 receptor levels were reduced in glomerular endothelial cells in diabetic 
mice through activation of protein kinase C (PKC) [169]. Exendin-4, a long acting 
GLP-1 analogue was shown to act through cyclic adenosine mono phosphate (cAMP) 
induced phosphorylation of c-Raf, which inhibits angiotensin II induced activation of 
phospho-c-Raf in diabetic mice and prevents progression of diabetic nephropathy. 
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They showed that exendin-4 did not improve expression of GLP-1 receptor levels in 
diabetic mice overexpressing protein kinase C in their glomerular endothelial cells 
(EC-PKCß2Tg). However, exendin-4 was still able to reduce diabetic glomerular 
changes in these mice in spite of reduced GLP-1 receptor levels suggesting alternative 
cAMP independent pathways in addition to cAMP dependent pathways [169].  
 
GLP-1 also exerts a protective effect on the kidneys through its anti inflammatory 
action. It has been shown that exendin-4 ameliorated albuminuria and glomerular 
changes in a streptozotocin induced diabetic rat model. This was accompanied by 
reduced macrophage infiltration and release of pro-inflammatory cytokines by 
macrophages through activation of GLP-1 receptors. It was also shown that 
intracellular adhesion molecule-1 (ICAM-1) production and expression on glomerular 
endothelial cells was reduced by activation of GLP-1 receptors on these cells [170]. 
GLP-1 receptor signaling via AMP activated protein kinase has been shown to 
increase nitric oxide (NO) production by endothelial cells resulting in vascular 
relaxation suggesting a direct role in improving hypertension [171]. Furthermore it 
has been shown that liraglutide increases atrial natriuretic peptide (ANP) release from 
cardiac atria and there is a meal induced increase in ANP secretion in wild type mice 
along with increased urinary sodium excretion, which was not seen in GLP1r(-/-) 
mice [172]. Hence GLP-1 receptor agonists may exert renal benefit by improving 
blood pressure and endothelial relaxation in small and large blood vessels. However it 
is to be noted that in human subjects, liraglutide promotes natriuresis without 
increasing circulating levels of ANP suggesting alternative mechanisms for the 
natriuresis [173]. 
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5.4.2 Evidence from clinical studies 
 
Exenatide, a GLP-1 agonist has also been shown to reduce urinary albuminuria, 
collagen IV and TGFß excretion in patients with type 2 diabetes and 
microalbuminuria in comparison with glimepride, a sulfonylurea, after attaining 
similar glycaemic control [174]. GLP-1 infusion over a 2-hour period has been shown 
to increase urinary sodium excretion and reduce serum angiotensin II concentration in 
healthy men providing clinical evidence of its effects on the renin angiotensin system 
[175]. The ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) study 
comparing the effects of lixisenatide, a GLP-1 agonist, versus placebo in reducing 
cardiovascular mortality in 6000 patients with acute coronary syndrome over a two 
year follow up period, did not show any benefit. These data were presented at the 
American Diabetes Association (ADA) 2015 scientific sessions. More recently the 
results of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results) study were published, which showed 
cardiovascular morality benefit of liraglutide in 9340 patients who were randomly 
assigned to either liraglutide or placebo over a five-year period. In addition, this study 
also showed significant reduction in incidence of nephropathy compared to placebo 
[176].  
 
5.5 The enzymatic and non-enzymatic functions of DPP4 in diabetic 
nephropathy 
 
DPP4 has enzymatic and non-enzymatic attributes, which extend beyond inactivation 
of GLP-1 and GIP. Animal studies have shown that DPP4i are associated with 
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improvement in renal function. The study by Mega et al showed improvement in 
diabetic nephropathy in Zucker diabetic fatty rats (ZDF) although this was associated 
with improvement in glycaemic parameters [4].  Similarly Liu et al showed 
improvement in diabetic nephropathy in streptozotocin (STZ) induced diabetic rats 
treated with vildagliptin. However this was associated with elevated GLP-1 levels 
making it difficult to estimate the non GLP-1 mediated actions of DPP4 [177]. 
Linagliptin has been shown to prevent progression of chronic kidney disease in non 
diabetic rats with 5/6 nephrectomy, hence giving credence to the renoprotective 
benefit of DPP4i beyond their glucose lowering effect [178]. 
 
It has been demonstrated that DPP4 is expressed on the renal tubular brush border. It 
has also been shown that urinary excretion of an intact peptide substrate by mice 
lacking tubular brush border DPP4 was much higher than mice possessing DPP4, 
signifying the enzymatic role of tubular DPP4 over luminal substrates [179]. Mass 
spectroscopy based global peptide profiling of DPP4 knock out mice has revealed 
substrates, which may play a role in the pathogenesis of inflammation and more 
importantly in diabetic nephropathy. One such substrate that has been identified is 
meprin ß [180]. It has been shown that activated forms of pure recombinant meprin ß 
cleave PKC resulting in reduced PKC kinase activity [181]. It is known that PKC is 
increased in diabetic kidneys and hence meprin cleavage by DPP4 present on the 
tubular brush border may impact on protective benefits of uncleaved meprin and 
hence impact diabetic nephropathy. High mobility group box-1 (HMGB-1) is also a 
substrate of DPP4 [182]. It has also been established that HMGB-1 plays a significant 
role in inflammation in diabetic nephropathy [183]. It has been shown that tubular 
expression of HMGB-1 is increased in diabetes and it acts through toll like receptor 2 
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(TLR2) and toll like receptor 4 (TLR4) to activate downstream inflammatory 
pathways in diabetic nephropathy [115, 116]. HMGB1 also acts via receptor for 
advanced glycation end products (RAGE), which in turn activates reactive oxygen 
species [184]. It is therefore possible that DPP4i may modulate diabetic nephropathy 
through prevention of HMGB1 cleavage. 
 
With respect to the enzymatic properties of DPP4, several substrates have been found 
to be important mediators in immune function, inflammation, vascular repair and 
hypertension [185]. Brain natriuretic peptide (BNP 1-32) is a substrate of DPP4 and is 
cleaved to BNP 3-32. The uncleaved BNP is shown to be more natriuretic than the 
cleaved product in dogs and was also shown to significantly reduce blood pressure 
[186]. Stromal derived factor-1α (SDF-1α) has been shown to be a substrate of DPP4 
[187]. SDF-1α has also been shown to be a chemo attractant for progenitor cells and 
has been suggested to reduce infarct size in Wistar rats with an increased expression 
of SDF-1α in animals treated with linagliptin [188]. 
 
The non-enzymatic actions of DPP4 include interaction with other cellular proteins to 
exert adhesion molecule like functions and influence extracellular matrix deposition 
and remodeling [137]. 
 
It has been shown that linagliptin, a DPP4 inhibitor is able to ameliorate endothelial to 
mesenchymal transition and prevent kidney fibrosis in streptozotocin (STZ) induced 
diabetic mice. This was mediated through microRNA 29 induction and was achieved 
without alteration of blood glucose levels [189]. It has been shown that DPP4 binds 
with integrin ß1 and this complex activates TGFß in addition to increased expression 
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of vascular endothelial growth factor receptor-1 (VEGFR-1) [141]. TGFß signaling 
promotes fibrosis and VEGFR1 receptor activation promotes endothelial to 
mesenchymal transition [141]. Linagliptin has been shown to inhibit the DPP4-
integrin ß1 interaction blunting TGFß signaling and endothelial to mesenchymal 
transition [141]. 
 
Our group has shown that DPP4 is expressed in human kidney proximal tubular cells 
(HK2 cells) and that linagliptin is able to reduce high glucose induced conversion of 
latent to active TGFß and downstream reduction in fibronectin [190]. We have shown 
that linagliptin, a non-peptidomimetic DPP4 inhibitor, potentially reduces activation 
of TGFß by inhibiting the high glucose induced interaction of DPP4 with the cation 
independent mannose-6-phosphate receptor (CIM6PR) in HK2 cells. This results in a 
demonstrated reduction in downstream Smad2 signaling and consequent 
tubulointerstitial fibronectin deposition in an STZ induced diabetic eNOS -/- mouse 
model [8]. We have replicated similar renoprotective benefits using another DPP4 
inhibitor, saxagliptin, a peptidomimetic DPP4 inhibitor in a STZ induced diabetic 
eNOS -/- mouse model, suggesting that this is a class effect and extends across both 
peptidomimetic and non-peptidomimetic DPP4i [9]. However, it remains possible that 
the degree of renoprotection varies depending on factors including exposure of the 
DPP4 inhibitor to the tubular brush border membrane. 
 
It is well known that mortality in CKD is primarily related to cardiovascular disease 
[191]. Following the unexpected adverse cardiovascular outcomes reported with 
rosiglitazone, the FDA mandated trials aimed at determining major adverse 
cardiovascular outcomes with newer anti diabetic agents [102]. In 2009, the 
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RECORD (Rosiglitazone evaluated for cardiovascular outcomes in oral agent 
combination therapy for type 2 diabetes) study subsequently demonstrated no 
increased cardiovascular risk with the use of rosiglitazone.  Issues with trial design 
and data integrity led to an independent readjudication of the data in June 2013 [103]. 
This process demonstrated the importance of dedicated trials powered to look at 
major cardiovascular outcomes and hence this is an important focus for manufacturers 
of newer anti diabetic medications. The SAVOR-TIMI trial looked at cardiovascular 
outcomes of saxagliptin versus placebo in patients with risk factors for cardiovascular 
disease or who had a history of cardiovascular events. It did not show any difference 
in all cause or cardiovascular mortality although the incidence of heart failure was 
higher in patients treated with saxagliptin [104]. There was an improvement in 
albuminuria although this was in association with improvement in glycaemic control 
and potentially a direct result of this rather than due to a specific renoprotective 
benefit. Similarly the EXAMINE trial looked at cardiovascular outcomes in diabetic 
patients who were initiated on alogliptin after a myocardial infarction and showed no 
change in all cause or cardiovascular mortality. This showed non inferiority of DPP4i 
in relation to cardiovascular outcomes, although it did not reproduce the 
cardiovascular benefits touted by previous meta analyses. Moreover the changes in 
eGFR were similar in both placebo and DPP4 inhibitor treated groups [192]. 
 
There is one clinical trial currently involved in looking at the long-term 
cardiovascular and renal outcomes in patients with diabetes on linagliptin 
(CARMELINA, NCT01897532). This trial is being conducted in diabetic patients 
who are at high risk of cardiovascular events or who have had a prior cardiovascular 
event. The trial outcomes are major adverse cardiovascular events including 
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cardiovascular death, non fatal myocardial infarction and non fatal stroke. This trial 
will also assess renal outcomes including end stage kidney disease and a decline in 
renal function by greater than 50%. The trial is expected to be completed by 2018 and 
outcomes of this trial will confirm if linagliptin can offer cardiorenal protection.  
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Figure 5.1 
 
 
Figure 5.1: The incretin system 
Meal induced stimulation of glucagon like peptide-1 (GLP-1) secretion is short lasting 
due to deactivation of GLP-1 by dipeptidyl peptidase-4 (DPP-4). However DPP-4 
inhibitors prolong action of GLP-1 resulting in prolonged post meal insulin secretion. 
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Chapter 6: Linagliptin limits high glucose induced 
conversion of latent to active TGFβ through interaction with 
CIM6PR and limits renal tubulointerstitial fibronectin 
 
Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U. 
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Abstract  
 
Background 
In addition to lowering blood glucose in patients with type 2 diabetes mellitus, 
dipeptidyl peptidase 4 (DPP4) inhibitors have been shown to be antifibrotic. We have 
previously shown that cation independent mannose-6-phosphate receptor (CIM6PR) 
facilitates the conversion of latent to active transforming growth factor β1 (TGFβ1) in 
renal proximal tubular cells (PTCs) and linagliptin (a DPP4 inhibitor) reduced this 
conversion with downstream reduction in fibronectin transcription.  
 
Objective 
We wanted to demonstrate that linagliptin reduces high glucose induced interaction 
between membrane bound DPP4 and CIM6PR in vitro and demonstrate reduction in 
active TGFβ mediated downstream effects in a rodent model of type 1 diabetic 
nephropathy independent of high glycaemic levels. 
 
Materials and Methods 
We used human kidney 2 (HK2) cells and endothelial nitric oxide synthase knock out 
mice to explore the mechanism and antifibrotic potential of linagliptin independent of 
glucose lowering. Using a proximity ligation assay, we show that CIM6PR and DPP4 
interaction was increased by high glucose and reduced by linagliptin and excess 
mannose-6-phosphate (M6P) confirming that linagliptin is operating through an M6P-
dependent mechanism.  In vivo studies confirmed these TGFβ1 pathway related 
changes and showed reduced fibronectin, phosphorylated smad2 and phosphorylated 
smad2/3 (pSmad2/3) with an associated trend towards reduction in tubular atrophy, 
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which was independent of glucose lowering. No reduction in albuminuria, 
glomerulosclerotic index or cortical collagen deposition was observed.  
 
Conclusion  
Linagliptin inhibits activation of TGFβ1 through a M6P dependent mechanism. 
However this in isolation is not sufficient to reverse the multifactorial nature of 
diabetic nephropathy.  
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6.1 Introduction 
 
The incretin family, including glucagon like peptide 1 (GLP-1), gastrointestinal 
peptide (GIP) and dipeptidyl peptidase 4 (DPP4), are targets of recent glucose 
lowering drugs. The DPP4i are now well established as hypoglycaemic agents for use 
in patients with type 2 diabetes mellitus. The potential for DPP4i to offer beneficial 
effects beyond glucose lowering lies with the functional ability of DPP4 to cleave a 
host of peptides apart from GLP-1.  
 
DPP4 is a serine exopeptidase belonging to the S9B protein family, members of 
which cleave X-proline dipeptides from the N-terminus of polypeptides, such as 
chemokines, neuropeptides, and peptide hormones [193]. It is a 110-kDa type 11 
integral membrane glycoprotein and is expressed ubiquitously in most organs and cell 
types.  Importantly, DPP4 is therefore able to exert pleiotropic effects. DPP4 exists in 
both a soluble and membrane bound form, both of which are capable of proteolytic 
activity. The soluble form in the circulation is thought to arise from shedding of the 
membrane bound DPP4 and is the target for DPP4i as hypoglycaemic agents in 
clinical use [193]. In contrast, the membrane bound form of DPP4, expressed on the 
surface of many cell types including kidney tubular cells, endothelial cells and T cells 
[194], is of major interest with respect to the pleiotropic actions of DPP4. Membrane 
bound DPP4 also exerts non-enzymatic actions by virtue of colocalising with other 
membrane proteins and modulating their intrinsic actions [193]. 
    
It is widely accepted that transforming growth factor β1 (TGFβ1) is a major driver of 
fibrosis in diabetic nephropathy. We have recently reported that linagliptin, a DPP4 
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inhibitor, reduces high glucose induced active TGFβ1 in human kidney proximal 
tubular cells [195]. This translated to a downstream reduction in phosphorylated 
Smad2 (pSmad2) and fibronectin transcription and expression.  As high glucose 
induced total secreted TGFβ1 was unchanged by linagliptin, we postulated that the 
mechanism was related to interference with the conversion of latent to active TGFβ1. 
TGFβ1 is secreted in a latent form and requires a complex interplay of soluble 
signaling molecules in the activation process, which releases it from the latency 
associated peptide (LAP). Once released from the LAP, the unbound TGFβ1 can then 
bind to its receptor to initiate cell signaling via the Smad pathway. Several other 
molecules such as plasminogen, thrombospondin-1 (TSP-1) and the cation 
independent mannose-6-phosphate receptor (CIM6PR) [196] participate in this 
activation process. Among these candidate molecules, we showed that TSP-1 was not 
the likely target to explain the inhibition of latent to active TGFβ1 [195].  
     
The CIM6PR is a membrane protein that binds mannose-6-phosphate containing 
proteins (like DPP4 and LAP). We have shown in our previous studies that CIM6PR 
is central to the activation process of TGFβ1 in human kidney proximal tubular cells 
exposed to high glucose [197]. Given the fact that CIM6PR and DPP4 colocalise on 
the cell membrane [198], we sought to study the interaction between the two in 
context of high glucose and to delineate the mechanism by which linagliptin reduces 
active TGFβ1. We also extended our studies to include an in vivo model of diabetic 
nephropathy, and importantly compared the treatment group to a control group with 
matched glucose levels, to evaluate whether linagliptin has antifibrotic effects 
independent of its glucose lowering properties.  
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6.2 Materials and methods 
 
6.2.1 Cell Culture 
 
HK2 cells, a primary human proximal tubular cell line (American Type Culture 
Collection), were grown in Keratinocyte Serum Free Media supplemented with 
bovine pituitary extract 20-30µg/ml and epidermal growth factor 0.1-0.2ng/ml 
(Gibco, NY, USA) on coverslips and treated with 5mM glucose, 30mM glucose, 
30mM glucose plus 1 µM mannose-6 phosphate (M6P) (Santa Cruz) and 30mM 
glucose plus 30nM linagliptin (generously provided by Boehringer-Ingelheim, 
Germany) for 48 hours. The IC50 (half maximal inhibitory concentration) of 
linagliptin is 1nM and the final concentration in our cell culture system was 30nM 
[195]. Initial experiments were done using increasing concentrations of M6P ranging 
from 1nM to 1mM. A final concentration of 1µM was chosen. The rationale for 
adding M6P is to saturate the M6P binding sites on the CIM6PR. If linagliptin 
reduces the interaction between CIM6PR and DPP4 through a M6P mechanism, then 
an excess of free M6P in the cell culture system would reduce recognition of the M6P 
moiety on the DPP4 and hence reduce any CIM6PR: DPP4 interaction.  
 
6.2.2 Proximity ligation assay 
 
Duolink In situ Fluorescence kit (Sigma Aldrich, St. Louis, MO) was used as per 
manufacturer’s instructions. This is based on the principle that a pair of 
oligonucleotide labeled secondary antibody probes generate a signal only when the 
two probes have bound in close proximity to two primary antibodies attached to 
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proteins that are colocalised [199]. This technique allows direct visualisation of 
endogenous protein complexes in specific physiological environments. CIM6PR 
(Novus Biologicals, CO, USA) and DPP4 (Santa Cruz Biotechnology, USA) 
antibodies were initially optimised for immunofluorescence after cells were fixed 
using 3.7% paraformaldehyde, blocked with 2% bovine serum albumin and incubated 
with primary antibodies overnight. Importantly using the same antibodies, we ensured 
that linagliptin did not alter DPP4 protein expression with immunofluorescence. Cells 
were then incubated with both primary antibodies overnight, washed, incubated with 
secondary antibody probes and then subjected to ligation and amplification. 
Coverslips were mounted on slides using DAPI mounting medium and visualised with 
a confocal microscope. Images were acquired using Leica TCS SP5 confocal laser 
scanning microscope with the 63x/1.4NA objective using thick sections and adjusted 
to ensure that most of the nuclei were in the same Z plane. Resolution (1024x1024 
pixels) and parameter settings were standardised for all the images. A minimum of 
100 cells per sample was counted. The number of associations (visualised by red dots) 
was calculated using Image J Analyse Particles function and corrected for the number 
of cells, which were stained with DAPI. Experiments were done in triplicate and the 
data was presented as a mean + standard error. A p value of < 0.05 was considered 
significant. 
 
6.2.3 Animal model 
 
We used endothelial nitric oxide synthase knockout mice (eNOS -/-) as these have 
been shown to develop significant changes of diabetic nephropathy [200]. We used 
linagliptin (provided by Boehringer Ingelheim and at the recommended dose of 
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3mg/kg per day via oral gavage) as the DPP4 inhibitor in our studies. Current “best 
practice” for renoprotection rests with administration of an agent that blocks the 
renin-angiotensin-aldosterone (RAAS) system. Hence we included a comparator with 
Telmisartan (Sigma Aldrich, St. Louis, MO, at 3 mg/kg /day in drinking water). 
Animal groups were allocated as shown below for the renal studies, which was 
conducted for 24 weeks post induction of diabetes. Mice were given intraperitoneal 
injections of streptozotocin (STZ) at a dose of 55 mg/kg/day (Sigma Aldrich, St. 
Louis, MO) for 5 consecutive days at 7-8 weeks of age. This is the standard low dose 
STZ protocol validated by the Animal Models of Diabetic Complications Consortium. 
Blood glucose was tested using a glucometer (Accuchek Nano, Roche Diagnostics) 
one week after STZ through tail vein blood collection. Diabetes was defined by blood 
glucose greater than 16 mmol/L after a six-hour daytime fast. Mice with levels below 
16 mmol/L were excluded from the study. Fasting blood glucose levels were 
measured monthly. Long acting insulin (Insulin Glargine, Sanofi Aventis, Australia) 
was initiated as required from 10 weeks of age and was administered thrice weekly if 
the blood sugar exceeded 28 mmol/L or if they had lost weight greater than 25% from 
baseline. The aim was to match glycaemia and to maintain body weight and avoid 
ketonuria without achieving euglycaemia. Importantly, in all studies the glycaemic 
control of the diabetic animals was matched to assess specific renal effects of 
linagliptin independent of glycaemic control. The study was approved the Royal 
North Shore Hospital Ethics Committee (Protocol number 1203-009A). The 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
were followed in this study. Animals were anaesthetised using short inhalational 
anaesthesia with 2% Isoflurane for minor procedures. Animals were euthanized under 
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2% Isoflurane anaesthesia using cardiac puncture terminally. The groups were as 
below: 
 (i) Non - Diabetic (control):  12 animals 
(ii) Non - Diabetic (control) with linagliptin: 8 animals 
(iv) Diabetic: 12 animals 
(v) Diabetic with linagliptin: 9 animals 
(vii) Diabetic with telmisartan: 9 animals 
 
6.2.4 Measurement of physiological parameters 
 
Body weight was assessed monthly. Blood pressure was measured using a non-
invasive tail vein cuff method (CODA BP apparatus, Kent Scientific, USA) 
preterminally.  
 
6.2.5 Urine biochemistry 
 
Urine was collected at two different time points (4-6 weeks after initiation of 
treatment using metabolic cages and terminally using bladder puncture). Urine 
creatinine was measured using a picric acid method (Creatinine Companion, Exocell 
Inc., USA). Urine albumin was measured using ELISA (enzyme linked 
immunosorbent assay) (Albuwell, Exocell Inc., USA). 
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6.2.6 Kidney tissue harvest 
 
The un-perfused left kidney was harvested and snap frozen, after embedding in OCT 
compound. The right kidney was perfused with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde (PFA) and subsequently fixed in 10% neutral 
buffered formalin for 24-48 hours.  
 
6.2.7 Histology and immunohistochemistry 
 
Formalin fixed paraffin embedded (FFPE) kidney sections were stained with Periodic 
Acid Schiff and Sirius red stain.  Assessment of histological change was done in a 
blinded manner. The Glomerulosclerotic index (GSI) was calculated based on the 
formula, GSI = [(1 x N1) + (2 x N2) + (3 x N3) + (4 x N4)]/(N0 + N1 + N2 + N3 + 
N4), where Nx is the number of glomeruli with each given score for each section. 
Atrophic tubules were defined by dilatation, epithelial shedding and thinning of 
epithelium. Tubular damage was scored by counting the number of atrophic tubules 
per 400 tubules at 200x magnification.  The degree of interstitial collagen content in 
Sirius red stained slides was assessed in a blinded manner using Image J by 
identifying the percentage of interstitial collagen positive region at X 200 
magnification in 5 randomly selected regions. Immunohistochemistry for nuclear 
pSmad 2/3, was done on 4 micron paraffin embedded sections using goat anti-mouse 
pSmad 2/3 (SC11769-G, Santacruz Biotechnology, USA), after an overnight 
incubation at a concentration of 1:100, followed by donkey anti goat HRP tagged 
secondary antibody (Santacruz Biotechnology, USA at a concentration of 1:100). 
With respect to fibronectin, the primary antibody (Sigma, USA) was used at a dilution 
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of 1:1000 followed by anti rabbit secondary antibody at a dilution of 1:100 (Dako, 
Australia). The chromogenic reaction was carried out with 3,3′-diaminobenzidine 
chromogen (Dako, Australia) solution for 10 minutes.  
 
6.2.8 RNA isolation and RT-PCR analysis 
 
Total RNA was extracted from kidney tissue using Qiagen RNEasy Mini kit on an 
automated RNA extraction protocol using Qiacube. cDNA was synthesised using 
Roche Transcriptor First Strand cDNA synthesis kit (Roche, USA). The real time 
PCR was done using SYBR green (Bioline, Australia) for fibronectin (forward-
CACGGAGGCCACCATTACT and reverse-CTTCAGGGCAATGACGTAGAT) 
using actin (forward-CAGCTGAGAGGGAAATCGTG and reverse-
CGTTGCCAATAGTGATGACC) as the endogenous control. Primers were sourced 
from Sigma. The RT-PCR was performed using the AB7900 machine (Applied 
Biosystems, Australia).  
 
6.2.9 Western blot analysis 
 
Frozen tissue was homogenized with Quiagen Tissue Ruptur in 1.5 ml of cold 20mM 
HEPES buffer, pH 7.2, containing 1mM EGTA, 210mM mannitol, 70mM sucrose 
and centrifuged at 1.500 x g for 5 min at 4°C. Samples were then analysed by SDS 
gel electrophoresis (Novex, Life technologies, Australia) and electroblotted to 
Hybond Nitrocellulose membranes (Amersham Pharmacia Biotech, Bucks, UK). 
Membranes were then probed with pSmad2 (Ser465/467) antibodies (#3101,Cell 
Signaling Technology, USA) followed by HRP tagged anti rabbit antibody (Cell 
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Signaling Technology, USA). Membranes were stripped and probed for total Smad2 
(#5339, Cell Signaling Technology, USA). Proteins were visualized using Luminata 
Western HRP Substrate (Millipore) in a LAS 4000 image reader (GE Healthcare 
Life Sciences). Analysis was performed using Image J software (NIH, USA).  
 
6.2.10 Statistical analysis 
 
Statistical analysis was done using GraphPad Prism 6. Data are expressed as mean ± 
standard error of mean. A P value < 0.05 was considered statistically significant. 
Blood sugar profile during the study was measured using two way repeated measures 
ANOVA.  ANOVA with Bonferroni’s correction was used for all other statistical 
analysis.  
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6.3 Results 
 
6.3.1 M6P and linagliptin reduced high glucose induced CIM6PR:DPP4 
interaction in HK2 cells 
 
CIM6PR and DPP4 were both present on the cell membrane of HK2 cells. Proximity 
ligation assay revealed a significant increase in signal when cells were exposed to 
30mM glucose suggesting that CIM6PR and DPP4 were interacting under high 
glucose conditions (P<0.05). Linagliptin reduced this high glucose induced 
interaction (P<0.05). Excess M6P was also able to reduce this interaction (P<0.05), 
which suggests linagliptin is competing with M6P for binding at the CIM6PR.  This is 
shown in Figure 6.1A and B.   
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Figure 6.1  
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Figure 6.1  
(A) Proximity ligation assay demonstrating endogenous protein-protein interaction 
between membranous DPP4 and CIM6PR in HK2 cells visualised as individual 
fluorescent dots. This is increased in 30mM high glucose (HG) environment 
compared to control 5mM glucose (ctrl). M6P at 1µM and linagliptin at 30nM 
reduced the high glucose induced interaction. A quantitation of this is shown in (B). 
Data are represented as mean + standard error, n=3. *=P<0.05 compared to 5mM 
glucose, #=P<0.05 compared to 30mM glucose.  
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6.3.2 Blood glucose were elevated and matched in diabetic mice  
 
All diabetic mice had significantly elevated fasting blood glucose compared to control 
mice (P<0.05). All the diabetic mice had matched fasting blood glucose levels. This is 
shown in Table 6.1.  This was in the absence of urinary ketonuria (data not shown). 
 
6.3.3 Linagliptin did not reduce albuminuria in diabetic mice   
 
The diabetic mice showed significant terminal urinary albumin excretion in keeping 
with diabetic nephropathy compared to control mice (P<0.01). This was not improved 
by linagliptin. However telmisartan significantly reduced albuminuria (P< 0.01). This 
is summarised in Table 6.1.  
 
6.3.4 Physical parameters 
 
The diabetic mice exhibited the expected weight loss during the experiment in 
comparison to significant weight gain by control mice (P<0.01). The diabetic mice 
treated with linagliptin also demonstrated weight loss (P<0.01) and were not 
significantly different to untreated diabetic mice. However diabetic mice treated with 
telmisartan gained weight, which was significantly better than diabetic mice (P<0.01). 
The diabetic mice also showed significant renal hypertrophy compared to control 
mice (P<0.01). Linagliptin did not alter this significantly. Telmisartan reduced 
diabetes induced renal hypertrophy as signified by the normalised kidney/body weight 
ratio (P<0.01). The control and diabetic mice had comparable systolic blood pressure. 
These results are summarised in Table 6.1. 
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Table 6.1. Metabolic and physical parameters of mice 
 
 
Control 
 
Control + 
linagliptin 
 
Diabetic 
 
Diabetic + 
linagliptin 
 
Diabetic + 
telmisartan 
 
Gain in weight 
(grams) 5.86 ± 0.70 4.66 ± 0.70 
-0.68 ± 
0.63** 
-0.53 ± 
0.60** 2.20 ± 0.64
## 
Left kidney/ body 
weight ratio (%) 0.84 ± 0.05 0.81 ± 0.03 1.07 ± 0.06** 0.97 ± 0.05 0.83 ± 0.02
## 
Average blood sugar 
(mmol/L) 9.9 ± 0.1 10.2 ± 0.1 20.9 ± 0.9* 22.4 ± 0.7* 22.4± 1.1* 
Systolic BP (mm Hg) 115.6 ± 2.7 115.0 ± 3.2 111.1 ± 4.4 102.9 ± 2.5 101.3 ± 4.9 
24 hour urine 
albumin excretion 
(µg/day) 
463.4 ± 
105.7 
360.8 ± 
80.6 
2319 ± 
438.3** 2238 ± 226
 766.4 ± 
152.3## 
 
Values are shown as mean ± SEM  
*=P<0.05 vs control 
**=P<0.01 vs control  
##=P<0.01 vs diabetic 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 123 
6.3.5 Linagliptin did not reduce glomerulosclerosis in diabetic mice 
 
The diabetic mice had significant glomerulosclerosis compared to control mice 
(P<0.01). Linagliptin did not ameliorate the degree of glomerulosclerosis in diabetic 
mice. Telmisartan showed a significant improvement in the diabetic animals (P<0.01). 
These results are shown in Figure 6.2. 
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Figure 6.2 
 
 
 
 
 
 
	 125 
Figure 6.2. Diabetic mice demonstrated increased glomerulosclerosis, which was 
improved by telmisartan but not by linagliptin as demonstrated by quantification of 
glomerulosclerosis by glomerulosclerotic index. Representative photographs of PAS 
stained sections for control (ctrl), control + linagliptin (ctrl + lina), diabetic (dm), 
diabetic + linagliptin (dm + lina) and diabetic + telmisartan (dm + tel) groups are 
shown (Magnification=original X400). Data are expressed as mean ± SEM with 
**=P<0.01 vs ctrl, ##=P<0.01 vs dm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 126 
6.3.6 Linagliptin partially reduced tubular atrophy in diabetic mice 
 
Diabetic mice had significant tubular atrophy (P<0.05). Although both linagliptin and 
telmisartan showed a reduction in diabetic tubular atrophy, this change did not reach 
statistical significance.  These results are shown in Figure 6.3.  
 
Figure 6.3 
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Figure 6.3. Diabetic mice demonstrated tubular atrophy, which was partially reduced 
by linagliptin and telmisartan.  Representative photographs of PAS stained sections of 
tubulointerstitium for control (ctrl), control + linagliptin (ctrl + lina), diabetic (dm), 
diabetic + linagliptin (dm + lina) and diabetic + telmisartan (dm + tel) groups are 
shown (Magnification=original X 200). Quantification of tubular atrophy in all 
groups was done by counting the number of atrophic tubules per 400 tubule count 
(Data are expressed as mean ± SEM with *=P<0.05 vs ctrl). 
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6.3.7 Linagliptin reduced tubular pSmad 2/3 expression (a marker of 
transforming growth factor beta activation) in diabetic mice 
 
Diabetic mice showed significant renal nuclear expression of pSmad 2/3 (P<0.01), 
signifying TGFβ signaling. Both linagliptin and telmisartan treated mice showed a 
significant reduction in pSmad2/3 expression (both P<0.01). These results are shown 
in Figure 6.4A. Western blot analysis of pSmad 2 expression showed a trend towards 
increased expression in diabetic mice, which was ameliorated to some extent by 
linagliptin (P=0.08), (Figure 6.4B). The results from the Western blot analysis were 
consistent with the findings from immunohistochemistry. 
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Figure 6.4  
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Figure 6.4 
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Figure 6.4  
A) Diabetic mice demonstrated increased pSmad2/3 nuclear expression with 
immunohistochemistry, which was reduced by linagliptin and telmisartan.  
Representative photographs for control (ctrl), control + linagliptin (ctrl + lina), 
diabetic (dm), diabetic + linagliptin (dm + lina) and diabetic + telmisartan (dm + tel) 
groups are shown (Magnification=original X 200). Quantification was done by 
counting the number of positive nuclei at X200 magnification. Data are expressed as 
mean ± SEM with **=P<0.01 vs ctrl,  ##=P<0.01 vs dm  
B) Diabetic mice showed a trend towards increase in pSmad 2/total smad2 expression 
compared to control mice and a reduction with both linagliptin and telmisartan. This 
trend was consistent with the immunohistochemistry findings but did not reach 
statistical significance. Quantification was done using Image J. Data are expressed as 
mean ± SEM, n=6.  
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6.3.8 Linagliptin reduced fibronectin transcription and expression in diabetic 
mice 
 
Diabetic mice showed significantly increased renal cortical transcription of 
fibronectin mRNA in comparison to control mice (P<0.01). This was significantly 
improved in diabetic mice treated with linagliptin (P<0.05) and telmisartan (P<0.01). 
These data are shown in Figure 6.5A. In keeping with this, there was also a significant 
increase in tubulointerstitial fibronectin expression in diabetic mice (P<0.01), which 
was significantly reduced with linagliptin (P<0.05). These results are shown in Figure 
6.5B.   
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Figure 6.5  
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Figure 6.5 
 
 
 
 
 
 
 
 
 
	 135 
Figure 6.5  
(A) Diabetic mice demonstrated increased cortical fibronectin mRNA transcription by 
real time PCR. This was significantly reduced by linagliptin and telmisartan.  
(B) There was a significant increase in tubulointerstitial FN expression measured by 
immunohistochemistry in the diabetic animals and this was reduced with linagliptin. 
Representative photographs for control (ctrl), control + linagliptin (ctrl + lina), 
diabetic (dm), diabetic + linagliptin (dm + lina) and diabetic + telmisartan (dm + tel) 
groups are shown (Magnification=original X 200). Data are expressed as mean ± 
SEM with **=P<0.01 vs ctrl, #=P<0.05 vs dm, ##=P<0.01 vs dm. 
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6.3.9 Linagliptin did not reduce tubulointerstitial collagen deposition in diabetic 
mice  
 
Collagen I was increased in diabetic mice compared to control values (P<0.01). 
Telmisartan reduced collagen I deposition (P<0.05). This is shown in Figure 6.6A.  
Diabetic mice demonstrated an expected increase in renal picrosirius staining 
(collagen I and III) in comparison to control mice (P<0.01). Neither linagliptin nor 
telmisartan reduced picrosirius staining.  This is shown in Figure 6.6B.  
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Figure 6.6  
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Figure 6.6  
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Figure 6.6  
(A) Diabetic mice showed increased collagen I and (B) picrosirius staining. 
Linagliptin did not change either. Telmisartan reduced collagen I expression. 
Representative photographs of collagen I and tubulointerstitial picrosirius red stain for 
control (ctrl), control + linagliptin (ctrl + lina), diabetic (dm), diabetic + linagliptin 
(dm + lina) and diabetic + telmisartan (dm + tel) groups are shown 
(Magnification=original X 200). Quantification was done using Image J. Data are 
expressed as mean ± SEM with **=P<0.01 vs ctrl, #=P<0.05 vs dm. 
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6.4 Discussion 
 
These data provide new knowledge on the mechanism by which the DPP4 inhibitor, 
linagliptin, reduces active TGFβ1 and downstream renal fibrotic markers. An 
important aspect of this novel finding is that the interaction between CIM6PR and 
DPP4 is “switched on” by high glucose, and hence is maximally modulated by 
linagliptin in this environment. In the presence of excess M6P, the CIM6PR binding 
sites become saturated, resulting in the reduction in CIM6PR/DPP4 interaction, which 
would suggest that the interaction is occurring through a M6P residue on the DPP4 
molecule. The fact that linagliptin also reduced this interaction, suggests a M6P 
mediated mechanism which is independent of GLP-1 as our in vitro system is lacking 
in GLP-1. This finding is also confirmed in our in vivo model of diabetic 
nephropathy. Linagliptin was able to reduce renal cortical fibronectin transcription 
and tubular pSmad2/3 expression on immunohistochemistry. We also noted a trend 
towards reduction in pSmad2 expression on western blot analysis of whole kidney 
tissue. These findings are suggestive of inhibition of active TGFβ1 signaling. There 
was also a concomitant trend towards a reduction in tubular atrophy.  Importantly this 
anti-fibrotic trend was independent of glucose or blood pressure lowering.  
 
The renal effects of DPP4 inhibition have been previously explored in animal models 
of Type 1 and Type 2 diabetes. Both studies that have looked at the effect of DPP4 
inhibition (using vildagliptin and sitagliptin) show renoprotection.  However the 
HbA1c in the DPP4 inhibitor treated diabetic animals was lower than in the diabetic 
control animals [4, 177]. So in both of these in vivo studies it is difficult to conclude 
that the renal effects of DPP4 inhibition are independent of glucose lowering. 
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Kanasaki et al investigated the antifibrotic effect of linagliptin in a type 1 model of 
diabetic nephropathy. This study demonstrates that linagliptin after 4 weeks 
ameliorated diabetic kidney fibrosis independent of glucose lowering and this was in 
association with the inhibition of endothelial–mesenchymal transition and the 
restoration of microRNA29 a/b/c [189]. Like this study, the advantage of our 
experimental design is ensuring that the glucose levels are matched so the renal 
findings are not because of expected changes one would see with glucose lowering 
itself. In contrast to Kanasaki et al our study has a much longer duration of treatment 
(20 weeks) with linagliptin in the diabetic mice.  
    
The potential advantage over renin-angiotensin blockade such as telmisartan or other 
anti-fibrotic therapies targeting TGFβ1, such as monoclonal antibodies, is the finding 
that CIM6PR and DPP4 interaction seems to be occurring selectively in context of 
high glucose and hence maximally modulated by linagliptin during hyperglycaemia.	
Specifically targeting TGFβ1 utilizing antibodies is challenging clinically because of 
the complexity of its biological role in various organs. 	Non-selective targeting of 
TGFβ is unlikely to be a promising therapeutic strategy as TGFβ1 knockout is a lethal 
phenotype [201] and drugs that non-specifically target TGFβ1 including monoclonal 
antibodies result in cancer, inflammation and autoimmune disease. Hence more 
targeted therapies are required.  One strategy to overcome this is to exploit the fact 
that different cells activate latent TGFβ1 using different proteins. For example, unlike 
the kidney proximal tubular cells, the immune system regulates TGFβ1 through 
integrins rather than CIM6PR [202], highlighting the potential for DPP4i as 
antifibrotic in a high glucose environment being limited to CIM6PR dependent 
TGFβ1 activation. In terms of using M6P analogues directly to achieve the same 
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effect as linagliptin, their use is currently limited by a short half-life, low 
bioavailability and poor receptor binding [203, 204]. 
    
Although our study suggests that linagliptin has anti-TGFβ1 signaling effects in the 
kidney, we did not see any significant change in the glomerulosclerotic index or 
tubulointerstitial collagen deposition and albuminuria, which reflects the 
multifactorial aetiology of diabetic nephropathy. The polyol pathway is activated in 
cells such as the proximal tubular cells where glucose entry is independent of insulin. 
So, this finding is in keeping with our hypothesis and previous findings that DPP4 
inhibition is more likely to alter extracellular mediators such as TGFβ1 but not the 
intracellular regulation induced by hyperglycaemia [195]. Hence we would propose 
that effective treatments to limit diabetic nephropathy necessarily involve targeting 
multiple pathophysiological pathways, which include inhibition of membrane bound 
DPP4. 
    
Our study has a few limitations. We have shown indirectly rather than directly how 
linagliptin influences the interaction between CIM6PR and DPP4. Linagliptin binds to 
an internalised site in the enzyme and removed from the M6P moiety on the DPP4 
molecule and does not result in significant conformational change (communication 
from Boehringer-Ingelheim, Germany). So although our data support a M6P related 
mechanism, this could be through inhibiting either an enzymatic or non-enzymatic 
property of DPP4. Similar findings were published by Ishibashi et al where blocking 
the interaction of DPP-4 with M6P/IGF-IIR by the addition of excess amount of free 
M6P or M6P/IGF-IIR-Ab completely inhibited the DPP-4-induced increase in 
superoxide generation in HUVECs [205]. It is also important to appreciate that whilst 
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our in vitro data supports a non GLP-1 mediated mechanism, when linagliptin is 
administered in vivo it results in raised GLP-1 levels as expected. Hence our findings 
do not delineate between a GLP-1 and non GLP-1 mediated mechanism. However, 
this is mechanistically irrelevant when considering human application.  
    
In summary, we propose novel mechanistic data that add to the existing body of 
knowledge that DPP4 inhibition with linagliptin can inhibit the TGFβ1 related fibrotic 
pathway in diabetic nephropathy. Clinical trials are in progress to determine whether 
linagliptin impacts on renal and cardiovascular (ClinicalTrials.gov Identifier: 
NCT01897532) outcomes. If this is also borne out in clinical trials, DPP4 inhibition 
with linagliptin may have an added advantage in those at risk of diabetic nephropathy.  
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Abstract   
 
Aim 
In addition to lowering blood glucose in patients with type 2 diabetes mellitus, 
dipeptidyl peptidase 4 inhibitors (DPP4i) have been shown to be antifibrotic and anti-
inflammatory. We have previously shown that DPP4 inhibition in human kidney 
proximal tubular cells exposed to high glucose reduced fibrotic and inflammatory 
markers. Hence we wanted to demonstrate renoprotection in an in vivo model.  
 
Methods 
We used a type 1 diabetic animal model to explore the renoprotective potential of 
saxagliptin independent of glucose lowering. We induced diabetes in eNOS -/- mice 
using streptozotocin and matched glucose levels using insulin. Diabetic mice were 
treated with saxagliptin and outcomes compared to untreated diabetic mice.  
 
Results 
We provide novel data that saxagliptin limits renal hypertrophy, TGFβ related fibrosis 
and NF-κBp65 mediated macrophage infiltration. Overall there was a reduction in 
histological markers of tubulointerstitial fibrosis. There was no reduction in 
albuminuria or glomerulosclerosis.  
 
Conclusion 
Our findings highlight the potential of DPP4 inhibition as additional therapy in 
addressing the multiple pathways to achieve renoprotection in diabetic nephropathy.  
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7.1 Introduction 
 
Newer glucose lowering agents increasingly used in the treatment of patients with 
Type 2 diabetes mellitus target the incretin system. These drugs include the glucagon-
like peptide 1 (GLP-1) analogues and (DPP4i). The incretin hormone GLP-1 
promotes insulin release and inhibits glucagon secretion in a glucose dependent 
manner, resulting in the regulation of glucose after meals. Although DPP4i were 
originally designed to lower blood glucose by raising GLP-1 levels, they have 
pleiotropic actions by virtue of their ability to cleave peptides that have a 
proline/alanine at the penultimate position in the amino terminal end.  
       
DPP4 is a serine exopeptidase belonging to the S9B protein family, members of 
which cleave X-proline dipeptides from the N-terminus of polypeptides, such as 
chemokines, neuropeptides, and peptide hormones [193]. It is a 110-kDa type 11 
integral membrane glycoprotein and is expressed ubiquitously in most organs and cell 
types. Importantly, DPP4 is therefore able to cleave a host of other peptides and exert 
pleiotropic effects independently of GLP-1. Additionally, DPP4 exists as 2 forms 
(soluble and membrane bound) both of which are capable of proteolytic activity. The 
soluble form in the circulation is thought to arise from shedding of the membrane 
forms and is responsible for the glucose lowering effect of the DPP4i in clinical use. 
In contrast, the membrane bound form of DPP4 expressed on the surface of many cell 
types including the apical/brush border surface of the kidney proximal tubular cell 
(PTC) [206], endothelial cells and T cells [194] is of major interest with respect to the 
pleiotropic actions of DPP4. We have recently shown in human kidney proximal 
tubular cells exposed to high glucose that linagliptin reduces activation of TGFβ and 
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fibronectin production[195], which is likely due to a cation independent mannose 6 
phosphate receptor related mechanism.  Hence DPP4 also possess non-enzymatic 
properties and are ideally suited to be used as antifibrotic agents in both type 1 and 
type 2 diabetes mellitus. This concept is highly attractive given that a third of patients 
with diabetes suffer kidney complications such as diabetic nephropathy requiring 
renal replacement therapy. 
        
DPP4i differ significantly in their pharmacokinetic profiles. While the different routes 
of clearance may not be immediately relevant to glucose lowering effects, it may be 
directly relevant for renal protection. A DPP4 inhibitor that is not filtered and cleared 
by the kidneys may not gain access to luminal DPP4 that is bound to the brush border 
membrane of the proximal tubular cells. For this reason, we chose to use saxagliptin 
in our experiments, a DPP4 inhibitor which is filtered and excreted by the kidneys.  
       
An important concept in interpreting studies to date evaluating renoprotective benefits 
with DPP4 inhibition is the confounding effect of concomitant glucose lowering. 
There are two studies that have looked at the effect of DPP4 inhibition (using 
vildagliptin and sitagliptin) on the diabetic animal kidney and both show 
renoprotection.  Liu et al reported that vildagliptin was renoprotective with a 
reduction in albuminuria and improvement in the histological changes in the kidney, 
which were associated with reduced DPP4 activity and raised GLP-1 levels. The 
authors concluded that these changes were probably not attributable to the 
hypoglycaemic effect of vildagliptin. However the HBA1c in the diabetic group was 
12.1% (compared to 4.7% in the control group) and the diabetic plus vildagliptin 
8mg/kg/day was 10.4%, which was slightly lower than the diabetic group although 
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this was not significant [177]. We know from the UKPDS study that even small 
changes in HBA1c levels can lead to significant differences in the development in 
diabetic microvascular complications [154].  The other study by Mega et al, done in a 
type 2 animal model of diabetes (Zucker diabetic fatty rat), also showed that DPP4 
inhibition (chronic low-dose sitagliptin treatment) was able to ameliorate diabetic 
nephropathy but once again the changes were associated with a significant reduction 
of HBA1c levels in the obese diabetic sitagliptin treated group (HBA1c 10.9% vs 
9.1% in the diabetic alone group) [4]. So in both these in vivo studies it is difficult to 
conclude that the renal effects of DPP4 inhibition lie above and beyond glucose 
lowering. The advantage of our experimental design is ensuring that the glucose 
levels are matched to remove this confounding variable when interpreting whether an 
independent renoprotective effect exists.  
 
7.2 Materials and methods 
     
7.2.1 Animal model  
 
All animal use and welfare adhered to the national Institute of Health Guide for the 
Care and Use of Laboratory Animals following a protocol reviewed and approved by 
the Institutional Ethics Committee at The Royal North Shore Hospital (Protocol 1203-
009A). Animal studies followed the 'Principles of Laboratory animal care' (NIH 
publication Volume 25, No. 28 revised 1996). We used male endothelial nitric oxide 
synthase knockout mice (eNOS -/-) as they have been shown to significantly 
reproduce changes of diabetic nephropathy. We used saxagliptin (provided by BMS 
and at the recommended dose of 10mg/kg per day via oral gavage) as the DPP4 
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inhibitor in our studies. Current “best practice” for renoprotection rests with 
administration of an agent that blocks the renin-angiotensin-aldosterone system 
(RAAS). Hence we included a comparator with telmisartan (3 mg/kg /day in drinking 
water), a dose we have previously shown does not induce lowering of BP [7].  Mice 
were allocated to groups as shown below and sacrificed at 24 weeks post induction of 
diabetes. Mice were given intraperitoneal injections of streptozotocin (STZ 
55 mg/kg/day; Sigma, St Louis, MO) for 5 consecutive days at 7-8 weeks of age. This 
is the standard low dose STZ protocol validated by the Animal Models of Diabetic 
Complications Consortium (AMDCC). Blood glucose was tested using a glucometer 
(Accuchek Nano, Roche) one week after STZ through tail vein blood collection. 
Diabetes was defined by blood glucose greater than 16 mmol/L after a six-hour 
daytime fast. Mice with blood glucose levels below 16 mmol/L were excluded from 
the study.	Treatment with saxagliptin and telmisartan commenced at week 12 of age 
once diabetes was established.   Fasting blood glucose levels were measured monthly. 
Long acting insulin (Insulin Glargine, Sanofi Aventis, Australia) was initiated as 
required from 10 weeks of age and was administered thrice weekly if the blood sugar 
exceeded 28 mmol/L or if they had lost weight greater than 25% from baseline. 
HBA1c was measured in mouse whole blood terminally using calorimetric method 
(Crystal Chem, USA). There was no difference in overall insulin requirements among 
the three diabetic groups. The aim was to match glycaemia, maintain body weight and 
avoid ketonuria without achieving euglycaemia. In all studies the glycaemic control 
of the diabetic animals was matched to assess specific renal effects of saxagliptin 
independent of glycaemic control. The groups were as below: 
 (i)       Non - Diabetic (control): 12 
(ii)     Non - Diabetic (control) with saxagliptin: 8 
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(iii)    Diabetic (control): 12 
(iv)    Diabetic with saxagliptin: 8 
(v)   Diabetic with telmisartan: 9 
 
7.2.2 Measurement of physiological parameters 
 
Body weight was assessed monthly. Blood pressure was measured using a 
noninvasive tail vein cuff method (CODA BP apparatus, Kent Scientific, USA) 
preterminally.  
 
7.2.3 Urine biochemistry 
 
Urine was collected at two different time points (4-6 weeks after initiation of 
treatment using metabolic cages and terminally using bladder puncture). Urine 
creatinine was measured using a picric acid method (Creatinine Companion, Exocell 
Inc., USA). Urinary glucose was measured using Abbot Architect C16000 analyser. 
Urine albumin was measured using Elisa (Albuwel, Exocell Inc., USA). 
 
7.2.4 Kidney tissue harvest 
 
The unperfused left kidney was harvested and snap frozen after embedding in OCT 
compound. The right kidney was perfused with phosphate buffered saline (PBS) 
followed by 4% paraformaldehyde (PFA) and subsequently fixed in 10% neutral 
buffered formalin for 24-48 hours.  
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7.2.5 Histology 
 
Formalin fixed paraffin embedded (FFPE) kidney sections were stained with 
Masson’s Trichrome, Picrosirius red and Periodic Acid Schiff.  Assessment of 
histological change was done in a blinded manner. The Glomerulosclerotic index 
(GSI) was calculated based on GSI = [(1 x N1) + (2 x N2) + (3 x N3) + (4 x N4)]/(N0 
+ N1 + N2 + N3 + N4), where N is the number of glomeruli with each given score for 
a given section. Immunohistochemistry for nuclear pSmad 2/3 was done on 4 micron 
paraffin embedded sections using goat anti mouse pSmad 2/3 (SC11769-G, Santacruz 
Biotechnology, USA) after an overnight incubation at a concentration of 1:100 
followed by donkey anti goat HRP tagged secondary antibody (Santacruz, USA at a 
concentration of 1:100). The chromogenic reaction was carried out with 3, 3′-
diaminobenzidine chromogen (Dako, Australia) solution for 10 minutes. F4/80 
assessment was done on frozen sections and anti-F4/80 was obtained from AbD 
Serotec (Oxford, U.K.) The degree of interstitial collagen content in Masson and 
Picrosirius stains were assessed in a blinded manner using Image J by identifying the 
percentage of interstitial collagen positive regions at X 200 magnification in 20 
randomly selected regions. The number of cells positive for F4/80 were counted in 20 
fields at X400 magnification. Cells positive for nuclear pSmad 2/3 and nuclear NF-
κBp65 were counted in 20 random fields at X200 magnification.  
 
7.2.6 Western blot analysis 
 
Frozen tissue was homogenized with Quiagen Tissue Ruptur in 1.5 ml of cold 20mM 
HEPES buffer, pH 7.2, containing 1mM EGTA, 210mM mannitol, 70mM sucrose 
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and centrifuged at 1.500 x g for 5 min at 4°C. Samples were then analysed by SDS 
gel electrophoresis (Novex, Life technologies, Australia) and electroblotted to 
Hybond Nitrocellulose membranes (Amersham Pharmacia Biotech, Bucks, UK). 
Membranes were then probed with pSmad2 (Ser465/467) antibodies (#3101,Cell 
Signaling Technology, USA) followed by HRP tagged anti rabbit antibody (Cell 
Signaling Technology, USA). Membranes were stripped and probed for actin (Goat 
anti mouse, Santa Cruz). Proteins were visualized using Luminata Western HRP 
Substrate (Millipore) in a LAS 4000 image reader (GE Healthcare Life Sciences). 
Analysis was performed using Image J software (NIH, USA).  
 
7.2.7 Statistical analysis 
 
Statistical analysis was done using GraphPad Prism 6. Data are expressed as mean ± 
standard error of mean. A P value < 0.05 was considered statistically significant. 
Blood sugar profile during the study was measured using two way repeated measures 
ANOVA.  ANOVA with Bonferroni’s correction was used for all other statistical 
analysis. 
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7.3 Results 
 
7.3.1 Blood glucose levels in diabetic mice 
 
All diabetic mice had significantly elevated fasting blood glucose compared to control 
mice (P<0.01). All the diabetic mice, had matched fasting blood glucose levels 
independent of treatment. Similarly the average HbA1c levels in diabetic mice in all 
groups were matched and significantly elevated compared to control mice (P<0.01). 
This is shown in Table 7.1.  This was in the absence of urinary ketonuria (data not 
shown).  
 
7.3.2 Effect of saxagliptin on albuminuria in diabetic mice 
 
The diabetic mice showed significant elevations in terminal urinary albumin excretion 
in keeping with diabetic nephropathy compared to control mice (P<0.01). This was 
not improved by saxagliptin. However telmisartan significantly reduced albuminuria 
(P< 0.01). These data are summarised in Table 7.1.  
    
7.3.3 Physical parameters 
 
The diabetic mice showed weight loss during the experiment in comparison to 
significant weight gain by control mice (P<0.01). The diabetic mice treated with 
saxagliptin gained only minimal weight and were not significantly different to 
untreated diabetic mice. However diabetic mice treated with telmisartan gained 
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weight, which was significantly better than diabetic mice (P<0.01). The diabetic mice 
groups had comparable systolic blood pressure independent of treatment (Table 7.1). 
 
7.3.4 Effect of saxagliptin on diabetic kidney hypertrophy 
 
The diabetic mice showed significant renal hypertrophy as measured by left 
kidney/body weight ratio compared to control mice (P<0.01). Both saxagliptin 
(P<0.05) and telmisartan (P<0.01) were able to reduce diabetic renal hypertrophy as 
signified by the improved kidney/body weight ratio. This is summarised in Table 7.1. 
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Table 7.1. Metabolic and physical parameters of mice.  
 
 
Control 
 
Control 
+saxagliptin 
 
Diabetic 
 
Diabetic 
+saxagliptin 
 
Diabetic 
+telmisartan 
 
Gain in weight 
(gram) 5.83 ± .70 
4.95 ± 
0.67 -0.68 ± .63** 
0.52 ± 
.60** 2.20 ± .64
## 
Left kidney/ body 
weight ratio (%) 0.84± .05 0.69 ± .03 1.07 ± .06** 0.89 ± .03
# 0.83 ± .02## 
Average blood sugar 
(mmol/L) 9.9 ± 0.1 9.9 ± 0.2 20.9 ± 0.9** 
21.7 ± 
1.1** 22.4± 1.1** 
HbA1c (%) 3.8 ± 0.56 4.1 ± 0.43 6.4 ± 0.46** 6.9 ± 0.55** 7.6 ± 0.64** 
Systolic BP 115.6 ± 2.7 117.1 ± 3.4 111.1 ± 4.4 110.4 ± 4.4 101.3 ± 4.9 
24 hour urine 
albumin excretion 
(µg/day) 
463± 105 497 ± 90 2319 ± 438** 2463 ± 574 766 ± 152
## 
 
Values are expressed as mean ± SEM  
**= P<0.01 vs control 
#=P<0.05 vs diabetic 
##=P<0.01 vs diabetic 
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7.3.5 Effect of saxagliptin in diabetic glomerulosclerosis 
 
The diabetic mice had significant glomerulosclerosis compared to control mice 
(P<0.01). Saxagliptin did not ameliorate the degree of glomerulosclerosis in diabetic 
mice. Telmisartan showed a significant improvement in the diabetic animals (P<0.01). 
These results are shown in Figure 7.1. 
 
Figure 7.1 
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Figure 7.1. Saxagliptin did not reduce glomerulosclerosis in diabetic mice. 
Diabetic mice demonstrated increased glomerulosclerosis, which was improved by 
telmisartan but not by saxagliptin as demonstrated by quantification of 
glomerulosclerosis by glomerulosclerotic index. Representative photographs of PAS 
stained sections for a) ctrl, b) ctrl + saxa, c) dm, d) dm + saxa and e) dm + tel groups 
are shown (Magnification=original X400). Data are expressed as mean ± SEM with 
**=P<0.01 vs ctrl, ##=P<0.01 vs dm.  
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7.3.6 Effect of saxagliptin on diabetic renal tubulointerstitial fibrosis 
 
Diabetic mice had significant tubulointerstitial fibrosis with Masson’s positive 
collagen staining (P<0.01) and Picrosirius red staining (P<0.01). Treatment with 
saxagliptin and telmisartan resulted in a significant reduction in collagen deposition. 
This is shown in Figure 7.2A (Masson’s staining) and 7.2B (Picrosirius red).   
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Figure 7.2A 
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Figure 7.2B 
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Figure 7.2. Saxagliptin improved tubulointerstitial fibrosis in diabetic mice.  
(A) Diabetic mice demonstrated increased Masson’s staining which was significantly 
improved by telmisartan and saxagliptin.  
(B) Diabetic mice demonstrated increased sirius positive collagen staining, with 
telmisartan and saxagliptin showing significant improvement. Representative 
photographs for a) ctrl, b) ctrl + saxa, c) dm, d) dm + saxa and e) dm + tel groups are 
shown (Magnification=original X200). Quantification was done using Image J 
software. Data are expressed as mean ± SEM with  **=P<0.01 vs ctrl, #=P<0.05 vs 
dm and ##=P<0.01 vs dm.  
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7.3.7 Effect of saxagliptin on tubular pSmad 2/3 expression in diabetic mice (a 
marker of transforming growth factor beta activation) 
 
Diabetic mice showed significant nuclear expression of pSmad 2/3 (P<0.01 vs 
control), signifying activation of the downstream fibrotic pathways of TGFβ. Both 
saxagliptin (P<0.01) and telmisartan (P<0.01) showed a statistically significant 
reduction in pSmad2/3 expression (Figure 7.3A). Diabetic mice showed significant 
increase in pSmad2 expression on western blot (P<0.05). Saxagliptin showed a trend 
towards improvement in diabetic mice (P=0.08). This is shown in Figure 7.3B. 
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Figure 7.3A 
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Figure 7.3B 
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Figure 7.3. Saxagliptin reduced tubular nuclear pSmad 2/3 expression (a marker 
of transforming growth factor beta activation) to control levels in diabetic mice. 
Western blot showed a trend towards improvement in pSmad2 expression in 
diabetic mice with saxagliptin. 
A) Diabetic mice demonstrated significantly increased pSmad2/3 nuclear expression 
with immunohistochemistry, which was significantly reduced to control levels by 
saxagliptin and telmisartan.  Representative photographs in a) ctrl, b) ctrl + saxa, c) 
dm, d) dm + saxa, e) dm + tel groups are shown (magnification X200). Quantification 
was done by counting the number of positive nuclei in 20 random fields at X200 
magnification.  
B) Western blotting showed a significant increase in pSmad2 expression in diabetic 
mice with saxagliptin showing a trend towards improvement (P=0.08 vs dm). 
Quantification of western blot was done using Image J software. Data are expressed 
as mean ± SEM with *=P<0.05 vs ctrl, **=P<0.01 vs ctrl,  ##=P<0.01 vs dm. 
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7.3.8 Effect of saxagliptin on fibronectin expression in diabetic mice 
 
Diabetic mice showed significant tubulointerstitial fibronectin expression signifying 
extracellular matrix deposition (P<0.01 vs control). Both saxagliptin and telmisartan 
showed significant improvement in fibronectin expression in diabetic mice (P<0.01) 
(Figure 7.4). 
 
Figure 7.4  
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Figure 7.4. Saxagliptin reduced fibronectin expression in diabetic mice. Diabetic 
mice demonstrated a significant increase in tubulointerstitial FN expression with 
immunohistochemistry and there was significant improvement with saxagliptin and 
telmisartan.  Data are expressed as mean ± SEM. Representative photographs in a) 
ctrl, b) ctrl + saxa, c) dm, d) dm + saxa, e) dm + tel groups are shown (magnification 
X200). Quantification was done using Image J software. Data are expressed as mean 
± SEM with **=P<0.01 vs ctrl, ##=P<0.01 vs dm. 
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7.3.9 Effect of saxagliptin on nuclear NF-κBp65 subunit translocation in diabetic 
mice 
 
Diabetic mice had a significant increase (P<0.01) in NF-κBp65 subunit translocation 
into the nucleus of proximal tubular cells indicating activation of tubular 
inflammation. Both saxagliptin and telmisartan reduced this significantly (P<0.01; 
Figure 7.5).  
 
Figure 7.5 
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Figure 7.5. Saxagliptin reduced nuclear NF-κBp65 subunit translocation to 
control levels in diabetic mice.  Diabetic mice showed significantly increased 
tubulointerstitial NF-κBp65 nuclear expression and this was significantly reduced 
with saxagliptin and telmisartan.  Representative photographs in a) ctrl, b) ctrl + saxa, 
c) dm, d) dm + saxa, e) dm + tel groups are shown with positive nuclei shown using 
arrows (magnification X400). Quantification was done by counting the number of 
positive nuclei in 20 random fields at X200 magnification. Positive nuclei are shown 
with arrows. Data are expressed as mean ± SEM with **=P<0.01 vs ctrl, ##=P<0.01 
vs dm. 
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7.3.10 Effect of saxagliptin on expression of F4/80 positive macrophages in 
tubulointerstitium of diabetic mice 
 
Diabetic mice had a significant increase (P<0.05) in F4/80 expression, which is a 
macrophage marker in diabetic mice. Saxagliptin reduced this significantly and this 
result is in keeping with the NF-κBp65 reduction (P<0.05; Figure 7.6).  
 
Figure 7.6 
 
 
	 171 
Figure 7.6. Saxagliptin reduced the number of F4/80 cell to control levels in 
diabetic mice. Diabetic mice showed significantly increased tubulointerstitial F4/80 
positive macrophages and this was significantly reduced with saxagliptin.  
Representative photographs in a) ctrl, b) ctrl + saxa, c) dm, d) dm + saxa, e) dm + tel 
groups are shown (magnification X400). Quantification was done by counting the 
number of positive cells in 20 random fields at X400 magnification.  Data are 
expressed as mean ± SEM with *=P<0.05 vs ctrl, #=P<0.05 vs dm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 172 
7.4 Discussion 
 
We provide novel data that saxagliptin limits renal hypertrophy, TGFβ related fibrosis 
and NF-κBp65 mediated macrophage infiltration in an animal model of diabetic 
nephropathy. There was a reduction in histological markers of tubulointerstitial 
fibrosis. It has been well described that glomerular and tubulointerstitial fibrosis occur 
sequentially and although there was no improvement in glomerulosclerosis in our 
model, the improvement in the tubulointerstitial markers may reflect the effect of 
DPP4 inhibition on filtered luminal profibrotic and proinflammatory mediators. In 
contrast to previously published literature, we have specifically designed our studies 
to show that these renal effects are independent of glucose lowering. As DPP4i are 
used clinically as oral glucose lowering agents in patients with type 2 diabetes 
mellitus the potential for these agents to have additional renoprotective effects makes 
them attractive therapeutic agents applicable to all patients with type 2 diabetes 
mellitus.  
     
There are several DPP4i available clinically and in context of the potential to prevent 
or reduce the burden of diabetic nephropathy it is important to appreciate the 
differences in terms of pharmacokinetics. Linagliptin has the advantage of being 
useful in patients with unstable renal impairment, as it is not predominantly cleared 
by the kidneys. In contrast, saxagliptin is freely filtered at the level of the kidney 
glomeruli and hence is able to access luminal membrane DPP4 which is abundantly 
expressed at the proximal tubular cell.  
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 In our animal model of diabetic nephropathy, we demonstrate that saxagliptin 
reversed several typical changes of diabetic nephropathy such as renal hypertrophy, 
fibrosis and inflammation, an effect that was also seen with telmisartan (current best 
practice therapy in diabetic nephropathy). Given the nature of the DPP4 enzyme, it is 
likely that the mechanism involves several putative peptides rather than one well 
defined pathway. In addition our model does not distinguish whether the renal 
benefits are mediated by or independent of GLP-1 acting at receptors in the kidney 
cells or vasculature. Apart from cleaving putative substrates, membrane bound DPP4 
can interact with other cell membrane proteins to signal intracellularly or 
extracellularly. We have previously published that DPP4 interacts with membrane 
cation independent mannose 6 phosphate receptor which is involved in the TGFβ 
activation process which is GLP-1 independent [195, 207]. This mechanism is in 
keeping with our in vivo data showing a significant reduction in pSmad2/3 expression 
resulting in a reduction of fibronectin expression.  
       
High mobility group box protein 1 (HMGB1) was identified as a DPP4 substrate by 
Marchetti et al several years ago with cleavage altering its biological function [182]. 
HMGB1 is a well described proinflammatory cytokine activating NF-κB in diabetes 
and has been shown to positively correlate with macro and microalbuminuria in 
patients with Type 1 diabetes [208]. We have previously shown in human kidney 
proximal tubular cells that DPP4 inhibition significantly reduced HMGB1 induced 
NF-κB activation. The mechanism of this is unclear as although HMGB1 is a 
substrate of DPP4, we showed no alteration in the cleaved product in our in vitro 
experiments [195]. It has been reported that saxagliptin enhances endothelial nitric 
oxide release resulting in lowering of blood pressure and inflammation [209]. 
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However this effect is unlikely in our model given that the animals are eNOS 
knockout mice.	  This reduction in NF--κB activation has been reproduced in our in 
vivo studies, which supports existing literature [210]. 
  
From a mechanistic perspective it is likely that the pleiotropic effects of DPP4 
inhibition are a combination of its enzymatic and non-enzymatic properties on several 
putative substrates and signaling pathways. It is also likely that the net effect of DPP4 
inhibition is dependent on the disease process and the extracellular substrate milieu 
and may explain our discordant findings, as we did not see a reduction in the 
glomerulosclerotic index or albuminuria. 
         
In summary we provide novel data that saxagliptin reduces renal hypertrophy, TGFβ 
related fibrosis and NF-κBp65 mediated macrophage infiltration in a model of 
diabetic nephropathy independent of glucose lowering. Although there was no 
reduction in overall glomerulosclerosis or albuminuria, the improvement in 
tubulointerstitial profibrotic and inflammatory markers highlights the potential of 
DPP4 inhibition as additional therapy in addressing the multiple pathways to achieve 
renoprotection in diabetic nephropathy.  
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Chapter 8: Summary and future directions 
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8.1 Summary 
 
Diabetic nephropathy is the commonest cause of progressive kidney disease and end 
stage kidney disease requiring dialysis in the world. The role of angiotensin 
converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers 
(ARBs) in attenuating diabetic nephropathy independent of their anti-hypertensive 
effects, have been proven through multiple trials over the last two decades [211-213]. 
Current treatment is modest at best and more effective therapeutic measures are 
critical to prevent kidney failure and dialysis in this population. The focus has shifted 
to interventions, which go beyond blood glucose control, anti hypertensive 
management and blockade of the renin angiotensin pathway in preventing diabetic 
nephropathy.  
 
The most important therapeutic developments in diabetes over the last decade have 
been the evolution of DPP4i and SGLT2i.  Both these drugs are oral hypoglycaemic 
agents that are safe to use in mild to moderate kidney disease. Indeed DPP4i retain 
significant efficacy in patients with ESKD, whereas as renal function declines the 
glucose lowering potential for SGLT2i is reduced. There have been significant 
advances and consequent evolution of knowledge in this area since the 
commencement of this PhD, which will be discussed later on in this chapter. The 
roles of both SGLT1 and SGLT2 in glucose metabolism in the kidney were reviewed 
in chapter 2. This Chapter has been peer reviewed and published in Current Opinion 
in Nephrology and Hypertension (Sodium glucose cotransporter 2 and the diabetic 
kidney) [5].This review examined the predominant role of SGLT2 in reabsorbing 
most of the filtered glucose from the luminal filtrate and also looked at the role of the 
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proximal tubule (PT) in the pathogenesis of diabetic nephropathy. The early and 
enhanced glucose reabsorption by the PT in states of hyperglycaemia and its 
contribution to glomerular hyperfiltration and tubular glycotoxicity was discussed. 
This chapter explored the role of SGLT2 inhibitors in preventing the initial 
physiological changes of diabetic nephropathy that was available at the time of 
commencement of this PhD. There were concerns regarding increased incidence of 
bladder and breast cancer with these agents although these fears are currently 
unfounded after clinical use of these drugs began over the last three years. 
 
The content of Chapter 3 has been peer reviewed and published in Expert Review in 
Clinical Pharmacology (Empagliflozin for the treatment of type 2 diabetes) [6]. 
Essentially, the clinical and basic scientific data available for empagliflozin, the 
SGLT2 inhibitor that we used in our studies, was reviewed. Empagliflozin was 
established as an effective agent to improve glycaemic control with robust evidence 
from animal studies and phase III human trials. There were no studies examining the 
renoprotective potential of SGLT2 inhibitors independent of the glucose lowering 
effect.  
 
The content of Chapter 4 has been peer reviewed and published in PLoS One 
(Inhibition of kidney proximal tubular glucose reabsorption does not prevent against 
diabetic nephropathy in type 1 diabetic eNOS knock out mice) [7]. The aim was to 
determine the role of SGLT2i in renoprotection over and above glycaemic control. 
This in vivo study was conducted in an endothelial nitric oxide deficient (eNOS -/-), 
streptozotocin induced type 1 diabetic mouse model. This model is endorsed by the 
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Animal Models of Diabetic Complications Consortium (AMDCC) and reproducibly 
develops diabetic kidney nephropathy.  
 
This mouse model developed all clinical characteristics of diabetic nephropathy, 
namely albuminuria, glomerulosclerosis, tubulointerstitial inflammation and fibrosis. 
In this study matched comparable high glucose levels were maintained in diabetic 
mice with the use of insulin. This was the first study designed to ensure that any renal 
effects that were observed were not confounded by concomitant glucose lowering. 
Moreover the renoprotective benefits that are demonstrated in the setting of matched 
glucose levels could also be applicable in chronic kidney disease of non diabetic 
etiology as the benefits are independent of glucose lowering and reflect alternative 
protective mechanisms. We demonstrated that while empagliflozin was effective in 
reducing insulin requirements in diabetic mice for the same matched high glucose 
levels, it did not ameliorate diabetic nephropathy in our model. In contrast diabetic 
mice treated with telmisartan, which is a current standard treatment for patients with 
diabetic nephropathy, demonstrated renoprotection. This study demonstrated that 
inhibition of proximal tubular glucose reabsorption was not associated with 
improvement in renal outcomes in the setting of persistently high blood glucose. A 
study by Vallon et al published in 2013 showed that empagliflozin improved diabetic 
nephropathy in a mouse model in accordance with improved glycaemic parameters 
reinforcing the well known fact that glycaemic control is essential to limit diabetic 
nephropathy [131]. Our study uniquely demonstrated that empagliflozin did not have 
renoprotective benefits independent of glucose lowering. However, it has to be noted 
that the eNOS -/- diabetic mouse model does not develop hyperfiltration [214]. Hence 
this study was not designed to evaluate the renal effects of empagliflozin on 
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glomerular hyperfiltration and hence the results obtained may have been limited by 
the model studied.  
 
Since publication of these findings, Cherney et al showed that by limiting proximal 
tubular sodium chloride (NaCl) reabsorption and hence increased distal delivery of 
NaCl, SGLT2i activate tubuloglomerular feedback with a consequent reduction in 
hyperfiltration [215]. It has also been shown that the sodium hydrogen exchanger 3 
(NHE3) in the proximal tubule is closely associated with SGLT2 and SGLT2 
mediated glucose uptake regulates NHE3 activity [216]. Hence reducing tubular Na 
reabsorption is a mechanism by which SGLT2i can have a positive impact on 
systemic hypertension in addition to reducing glomerular hyperfiltration by activation 
of tubuloglomerular feedback. Most importantly, in the recently published EMPA-
REG study, it has been shown that empagliflozin improved cardiovascular mortality 
in patients with diabetes and established cardiovascular disease compared to placebo 
[217]. This was observed in with the context of better glycaemic control. Whilst the 
absolute renoprotective benefits of SGLT2i may not be apparent in the setting of 
poorly controlled diabetes in an animal model, the overall long term cardiovascular 
and potentially renal benefits have thus been shown in humans. The EMPA-REG 
study was not powered to demonstrate renoprotective benefits, although a reduction in 
hard renal endpoints and a slowing in the progression of renal deterioration compared 
to the control group has been reported recently [218]. The CREDENCE study is 
designed to specifically determine whether the SGLT2i canagliflozin is 
renoprotective. It is currently recruiting patients with macroalbuminuria and various 
degrees of renal dysfunction (clinicaltrials.gov identifier: NCT02065791). This trial 
aims to recruit nearly 4200 patients who will be assigned to either canagliflozin 100 
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mg or placebo. It is important to appreciate that although SGLT2i block glucose 
reuptake and glycotoxicity at the level of the PTC, our study and the rest of the 
literature demonstrate that the inhibition of sodium reabsorption is more likely to 
account for the cardiovascular risk reduction and renoprotective effects [219].  
 
As alluded to above, DPP4i, which act via the gut based incretin pathway to sustain 
postprandial insulin secretion are increasingly used as second line therapy after 
metformin in patients with type 2 diabetes mellitus to improve glycaemic control. 
Chapter 5 reviews the available evidence regarding DPP4i in preventing diabetic 
nephropathy. DPP4 inhibition is potentially able to exert renoprotective effects 
through GLP-1 mediated and GLP-1 independent pathways. In addition, the 
enzymatic and non enzymatic role of DPP4i in reducing diabetic nephropathy in 
animal models was summarised. Our group has previously established that DPP4i 
reduce high glucose induced conversion of latent to active TGFß and therefore limit 
downstream pSmad2 expression in human kidney proximal tubular cells (HK2 cells) 
[190]. Our group has also previously demonstrated that cation independent mannose-
6-phosphate receptor (CIM6PR) is integral to the activation of TGFß in HK2 cells 
exposed to high glucose [197]. Given that CIM6PR is a membrane protein that binds 
mannose-6-phosphate containing proteins such as DPP4, the aim was to study the 
interaction between membrane bound DPP4 and CIM6PR and the role of DPP4i in 
preventing this interaction and thereby possibly preventing activation of TGFß, a 
prominent profibrotic cytokine in diabetic nephropathy. This mechanistic study was 
conducted in vitro and then validated in vivo. Once again, the animal model was 
designed to investigate renoprotective effects of DPP4i independent of its effect on 
glycaemic control. DPP4i differ in the way they bind to DPP4 as well as in their mode 
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of excretion. DPP4i can be divided into two groups based on whether they establish a 
covalent (vildagliptin, saxagliptin) or non covalent (sitagliptin, linagliptin and 
alogliptin) bond with the enzyme [148]. Unlike other DPP4i, linagliptin is not 
eliminated through the kidneys and so does not require a dose reduction in CKD. 
However, this also limits the exposure of linagliptin to the proximal tubular brush 
border membrane, which contains considerable membrane bound DPP4. Given 
pharmacological differences between DPP4i, 2 different clinically available DPP4i 
were employed in the in vivo model. 
 
The results presented in Chapter 6 have been peer reviewed and published in PLoS 
One (Linagliptin limits high glucose induced conversion of latent to active TGFß 
through interaction with CIM6PR and limits renal tubulointerstitial fibronectin) [8].  
It was shown, using a proximity ligation assay, that there was increased interaction 
between membrane bound DPP4 and CIM6PR when HK2 cells were exposed to high 
glucose. DPP4 inhibition using linagliptin reduced this interaction, conceptually 
through a M6P mediated mechanism.  This provided mechanistic data for the 
reduction in high glucose induced TGFß signaling observed in the presence of 
linagliptin. The biological relevance of these in vitro findings were then determined in 
a mouse model of diabetic nephropathy. High blood glucose levels were comparable 
and matched using long acting glargine insulin in linagliptin treated and untreated 
diabetic mice to demonstrate its benefits beyond its blood glucose lowering effect. 
Diabetic mice treated with linagliptin demonstrated a reduction in tubulointerstitial 
pSmad 2/3 expression and fibronectin transcription and protein expression, which are 
downstream markers of TGFß activation. However there was no improvement in 
diabetic glomerulosclerosis.  
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In Chapter 7, a similar in vivo study was undertaken using saxagliptin, a DPP4 
inhibitor predominantly eliminated by the kidneys. All data contained in Chapter 7 
has been peer reviewed and published (Saxagliptin reduces renal tubulointerstitial 
inflammation, hypertrophy and fibrosis in diabetes) [9]. There was reduced renal 
tubulointerstitial inflammation and fibrosis with reduced tubular pSmad 2/3 
expression and tubulointerstitial collagen deposition, which are downstream markers 
of TGFß activation. Saxagliptin also reduced nuclear NF-κB expression in tubular 
epithelial cells and tubulointerstitial macrophage infiltration, demonstrating 
improvement in inflammation associated with diabetic nephropathy. Similar to the 
study with linagliptin, there was no improvement in diabetic glomerulosclerosis.  
 
Collectively from these two studies on linagliptin and saxagliptin we demonstrated 
that DPP4i have renoprotective benefits at least in reducing tubulointerstitial fibrosis. 
The lack of improvement in glomerulosclerosis could be because DPP4 inhibition is 
more likely to alter extracellular mediators such as TGFß1 but not the intracellular 
regulation induced by hyperglycaemia highlighting the need to target multiple 
pathways concurrently to prevent nephropathy. Our results suggest that the 
renoprotective benefits of saxagliptin may be greater for linagliptin. We hypothesise 
that this may be due to greater exposure of the DPP4 inhibitor to the proximal tubular 
brush border membrane due to the renal excretion of saxagliptin. However, this 
hypothesis has not been specifically tested in the studies to date. 
 
A reduction in all cause mortality, cardiovascular and renal end points remain the key 
indicators of the long term benefits of any diabetic medication designed to lower 
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glucose. The large CARMELINA trial is in progress to determine whether linagliptin 
impacts on renal and cardiovascular outcomes (clinicaltrials.gov identifier: 
NCT01897532), and is due to be completed in 2018. This trial aims to recruit 8000 
patients with preexisting macrovascular disease and/or impaired renal function 
looking at major adverse cardiovascular effects (a composite of non-fatal myocardial 
infarction, non-fatal stroke, and cardiovascular death) as well as renal endpoints 
including 50% drop in eGFR or end stage kidney disease. Similarly the cardiovascular 
outcome of linagliptin is being compared to that of glimepride, a sulfonylurea drug in 
the CAROLINA trial (clinicaltrials.gov identifier: NCT01243424). This is currently 
the largest head to head trial comparing a DPP4 inhibitor to a sulfonylurea and is 
aimed at comparing the cardiovascular outcomes of these two classes of anti diabetic 
medications [220]. The MARLINA trial aims to identify the renal benefit of 
linagliptin in diabetic patients with suboptimal diabetic control, micro or 
macroalbuminuria and eGFR greater than 30 ml/min and who are on an angiotensin 
converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). The trial 
is currently complete and results will inform us of the potential renal benefit in 
patients with established diabetic nephropathy. 
 
8.2 Future directions 
 
A fixed dose combination of empagliflozin and linagliptin has been shown to have 
additional glycaemic benefits with improved weight loss and a low risk of 
hypoglycaemia [221]. Both these drugs have a complementary mode of action as the 
increased endogenous glucose production (EGP) due to SGLT2 inhibitors is offset by 
the DPP4i, which reduce glucagon secretion and reduce EGP [222]. 
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In this postgenomic era, therapy is shifting towards gene therapy. ISIS 388626 is an 
anti sense oligonucleotide (ASO) that targets human SGLT2 mRNA. Clinical trials 
are currently looking at the outcome of this ASO in the management of diabetes. In 
preclinical trials it has shown to reduce SGLT2 expression in a dose dependent 
manner in animal models without any toxic effects [223]. ASOs targeting glucagon 
receptors are in preclinical trials as they reduce the hepatic glucose production and 
can reduce insulin requirement (information from Ionis Pharmaceutical website).  
 
The treatment of diabetes and diabetic complications is entering an interesting era 
with newer therapeutic approaches such as gene therapy and significant clinical trial 
outcomes expected in the foreseeable future. Concurrent evaluation of short-term 
efficacy in lowering glucose as well as the longer term impacts on cardiovascular and 
renal endpoints are essential to improve the short-term and longer terms co-morbidity 
associated with diabetes mellitus.  
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